 
SOF/VEL in Pregnancy, Version 5.0 1 December 2  , 2020  
  
Phase 1 Pharmacokinetic Trial of Sofosbuvir/Velpatasvir  in Pregnant Women with 
Chronic Hepatitis C Virus Infection  
 
 
 
Protocol version  5.0 
 
 
Funding Agencies:  
Gilead Sciences  IN-US-342-5634  
 
National Institutes of Health: K12HD043441  
Building Interdiscip linary Research Careers in Women’s Health in Pittsburgh   
 
National Institutes of Health:  1R21  
Eunice Kennedy Shriver National Institut e of Child Health & Human Develo pment  
 
Pennsylvania Department of Health  
 
 
IND #: 146896  
 
IND Sponsor:   Catherine Chappe ll, MD, MS  
 
Protocol Chair:   Catherine Chappell, MD, MS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 2 December 2  , 2020  
  
 
Phase 1 Pharmacokinetic Trial of Sofosbuvir/Velpatasvir in Pregnant Women 
with Chronic Hepatitis C Virus Infection  
 
TABLE OF CONTENTS  
PROTOCOL SIGNATURE PAGE  ................................ ................................ ..............  4 
LIST OF ABBREVIATIONS AND ACRONYMS  ................................ ..........................  5 
PROTOCOL TEAM ROSTER  ................................ ................................ ....................  6 
PROTOCOL SUMMARY  ................................ ................................ ............................  7 
1 KEY ROLES  ................................ ................................ ...............................  11 
1.1 Protocol Identification  ................................ ................................ .................  11 
1.2 Funders, Sponsor and Monitor Identification ................................ ..............  11 
1.3 Clinical Laboratories  ................................ ................................ ..................  12 
2 INTRODUCTION  ................................ ................................ .......................  13 
2.1 Chronic Hepatitis C Infect ion in Pregnancy  ................................ ................  13 
2.2 Rationale  ................................ ................................ ................................ .... 14 
2.3 SOF/VEL  Fixed Dose Combination  ................................ ............................  17 
2.4 Clinical Studies  ................................ ................................ ..........................  18 
2.5 Rationale for Study Design  ................................ ................................ ........  20 
3 OBJECTIVES  ................................ ................................ .............................  21 
3.1 Primary Objective  ................................ ................................ .......................  21 
3.2 Secondary Objectives  ................................ ................................ ................  21 
4 STUDY DESIGN  ................................ ................................ ........................  22 
4.1 Identification of Study Design  ................................ ................................ ..... 22 
4.2 Summary of Major Endpoints  ................................ ................................ ..... 22 
4.3 Description of Study Population  ................................ ................................ . 23 
4.4 Time to Complete Accrual  ................................ ................................ ..........  23 
4.5 Expected Duration of Participation  ................................ .............................  23 
5 STUDY POPULATION  ................................ ................................ ...............  24 
5.1 Selection of the Study Population  ................................ ..............................  24 
5.2 Inclusion Criteria  ................................ ................................ ........................  25 
5.3 Exclusion Crit eria ................................ ................................ .......................  25 
6 STUDY MEDICATION  ................................ ................................ ...............  27 
6.1 Regimen ................................ ................................ ................................ ..... 27 
6.2 Administration  ................................ ................................ ............................  27 
6.3 Supply and Accountability  ................................ ................................ ..........  27 
6.4 Concomitant Medications  ................................ ................................ ...........  28 
7 STUDY PROCEDURES  ................................ ................................ ............  29 
7.1 Pre-screening  ................................ ................................ .............................  29 
7.2 Visit 1 - Screening (V1)  ................................ ................................ ...............  29 
7.3 Visit 2 - Enrollment (V2)  ................................ ................................ ..............  31 
7.4 Follow -up Visit s ................................ ................................ ..........................  31 
7.5 Follow -up Procedures for Participants Who Permanently Discontinue Study 
Medication ................................ ................................ ................................ .. 36 
7.6 Pharmacokinetics  ................................ ................................ .......................  37 
 
 
SOF/VEL in Pregnancy, Version 5.0 3 December 2  , 2020  
 7.7 Adherence Counseling and Assessment  ................................ ...................  38 
7.8 In Depth Interviews and Qualitative Analysis  ................................ .............  38 
7.9 Clinical Evaluations and Procedures  ................................ ..........................  39 
7.10  Laboratory Evaluations  ................................ ................................ ..............  39 
7.11  Specimen Collection and Processing  ................................ .........................  40 
7.12  Biohazard Containment  ................................ ................................ .............  40 
8 ASSESSMENT OF SAFETY  ................................ ................................ ...... 41 
8.1 Safety Monitoring  ................................ ................................ .......................  41 
8.2 Clinical Data and Safety Review  ................................ ................................  41 
8.3 Adverse Events Definitions and Reporting Requirements  .........................  42 
8.4 Expedited Adverse Event Reporting Requirements  ................................ ... 44 
8.5 Regulatory Requirements  ................................ ................................ ..........  44 
8.6 Social Harms Reporting  ................................ ................................ .............  44 
9 CLINICAL MANAGEMENT  ................................ ................................ ........  44 
9.1 Grading System  ................................ ................................ .........................  45 
9.2 Dose Modification Instructions  ................................ ................................ ... 45 
9.3 General Criteria for Permanent Discontinuation of St udy Medication  ........  45 
9.4 Permanent Discontinuation in Response to Adverse Events  .....................  45 
9.5 HIV-1 Infection  ................................ ................................ ...........................  46 
9.6 Criteria for Early Termination of Study Participation  ................................ .. 46 
10 STATISTICAL CONSIDERATIONS  ................................ ...........................  46 
10.1  Overview and Summary of Design  ................................ .............................  46 
10.2  Study Endpoint s ................................ ................................ .........................  46 
10.3  Sample Size  ................................ ................................ ...............................  48 
10.4  Participant Accrual and Retention  ................................ ..............................  48 
10.5  Data Analysis  ................................ ................................ .............................  48 
11 DATA HANDLING AND RECORDKEEPING  ................................ .............  49 
11.1  Data Management Responsibilities  ................................ ............................  49 
11.2  Source Documents and Access to Source Data/Documents  .....................  49 
11.3  Quality Control and Qu ality Assurance  ................................ ......................  50 
12 CLINICAL SITE MONITORING  ................................ ................................ .. 50 
13 HUMAN SUBJECTS PROTECTIONS  ................................ .......................  50 
13.1  Institutional Review Boards  ................................ ................................ ........  51 
13.2  Study Coordination  ................................ ................................ ....................  51 
13.3  Risk Benefit Statement  ................................ ................................ ..............  51 
13.4  Informed Consent Process ................................ ................................ .........  54 
13.5  Participant Confidentiality ................................ ................................ ...........  55 
13.6  Speci al Populations  ................................ ................................ ...................  55 
13.7  Compensation  ................................ ................................ ............................  56 
13.8  Communicable Disease Reporting  ................................ .............................  56 
13.9  Access to HIV -related Care ................................ ................................ ........  56 
13.10  Study Discontinuation  ................................ ................................ ................  57 
14 PUBLICATION POLICY  ................................ ................................ .............  57 
15 APPENDICES  ................................ ................................ ............................  57 
APPENDIX I: SCHEDULE OF STUDY VISITS AND EVALUATIONS (Mother)  ....... 58 
APPEN DIX II: SCHEDULE OF STUDY VISITS AND EVALUATIONS (Infant)  ........  60 
 
 
SOF/VEL in Pregnancy, Version 5.0 4 December 2  , 2020  
 Phase 1 Pharmacokinetic Trial of Sofosbuvir /Velpatasvir  in Pregnant Women with 
Chronic Hepatitis C Virus Infection  
 
 
Protocol Signature Page  
 
 
I will conduct the study in accordance with the pro visions of this protocol and all 
applicable protocol -related documents. I agree to conduct this study in compliance 
with United States (US) Health and Human Service regulations (45 CFR 46); 
applicable U.S. Food and Drug Administration regulations; standard s of the 
International Conference on Harmonization Guideline for Good Clinical Practice 
(E6); Institutional Review Board/Ethics Committee determinations; all applicable in -
country, state, and local laws and regulations; and other applicable requirements 15  
(e.g., US National Institutes of Health, Division of AIDS) and institutional policies.  
 
 
 
 
________________________________  ___________________________  
Catherine Chappell, MD, MS                       Date  
Protocol Chair/Principal Investigator  
University of Pittsburgh  
UPMC Magee -Womens Hospital  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SOF/VEL in Pregnancy, Version 5.0 5 December 2  , 2020  
 Phase 1 Pharmacokinetic Trial of Sofosbuvir/Velpatasvir in Pregnant Women 
with Chronic Hepatitis C Virus Infection  
 
LIST OF ABBREVIATIONS AND ACRONYMS  
 
ALT   Alanine tran saminase  
AST   Aspartate  transaminase  
AUC    Area under the curve  
DBS   Dried blood spot  
DAIDS   Division of AIDS  
DHHS   Department of Health and Human Services  
DNA    deoxyribonucleic acid  
DSMB   Data and Safety Monitoring Board  
EAE    Expedited adverse event  
FDA    Food and Drug  Administration  
GCLP   Good Clinical Laboratory Practices  
GCP    Good Clinical Practices  
HBsAg   Hepatitis B surface antigen  
HBV   Hepatitis B Virus  
HCV    Hepatitis C Virus  
HIV    Human immunodeficiency virus  
IDI   In-depth Interview  
INR   International nor malized ratio  
IoR    Investigator of Record  
IRB    Institutional Review Board  
ISR    Interim Study Review  
VEL   Velpatasvir  
SOF/VEL   Sofosbuvir /Velpatasvir  
mL    Milliliter  
MWH    Magee -Womens Hospital  
MWRI    Magee -Womens Research Institute  
NIAID    Nation al Institute of Allergy and Infectious Disease  
NIH    National Institutes of Health  
OHRP   Office of Human Research Protections  
PBMC    Peripheral Blood Mononuclear Cell  
PK   Pharmacokinetic  
PoR   Pharmacist of Record  
PTID    Participant identification numb er 
RNA    Ribonucleic acid  
SAE    Serious adverse event  
SOF   Sofosbuvir  
SOP    Standard operating procedure(s)  
SSP    Study -specific Procedures  
UPMC    University of Pittsburgh Medical Center  
 
 
SOF/VEL in Pregnancy, Version 5.0 6 December 2  , 2020  
 Phase 1 Pharmacokinetic Trial of Sofosbuvir /Velpatasvir  in Preg nant Women 
with Chronic Hepatitis C Virus Infection  
PROTOCOL TEAM ROSTER  
University of Pittsburgh Study Team  
Catherine Chappell, MD, MS c 
UPMC Magee -Womens Hospital  
300 Halket Street  
Pittsburgh, PA 15213 USA  
Phone: 412 -641-1809  
Fax: 412 -641-1133  
Email: chappellca@upmc.edu  
 
Sharon Hillier, PhD  
Magee -Womens Research Institute  
204 Craft Avenue  
Pittsburgh, PA 15213 USA  
Phone: 412 -641-8933  
Fax: 412 -641-6170  
Email: shillier@ mail.magee.edu  
 
Elizabeth Krans , MD, MSc  
UPMC Magee -Womens Hospital  
300 Halket Street  
Pittsburgh, PA 15213 USA  
Phone: 412 -641-4222  
Fax: 412 -641-1133  
Email: kransee@mail.magee.edu  
 
Debra L. Bogen, MD, FAAP, FA BM 
UPMC Children’s Hospital of Pittsburgh  
3414 Fifth Ave, CHOB 320  
Pittsburgh, PA 15213  
Office: (412) 692 -6932  
Fax: (412) 692 -5807  
Email: bogendl@upmc.edu  
 
University of Colorado  
Jennifer J. Kiser, PharmD, PhD  
Skaggs  School of Pharmacy and Pharmaceutical Sciences  
12850 E. Montview Blvd, V20 -C238  
Aurora, CO 80045  
Phone: (303) 724 -6131  
Fax: (303) 724 -6135  
Email: jennifer .kiser@cuanschutz.edu  
 
Gilead Sciences Study Team  
Sarjita Naik, PharmD, MPH  
Senior Medical Scientist,  Liver Disease  
Gilead Medical Affairs  
Phone: (412)526 -8541  
Email:  Sarjita.naik@gilead.com  
 
 
 
 
SOF/VEL in Pregnancy, Version 5.0 7 December 2  , 2020  
 Phase 1 Pharmacokinetic Trial of Velpatasvir /Sofosbuvir in Pregnant Women 
with Chronic Hepatitis C Virus Infection  
PROTOCOL SUMMARY  
 
Short Title:  Treatment of Chronic Hepatitis C during Pregnancy with 
Sofosbuvir /Velpatasvir  
 
Clinical Phase:  Phase 1  
 
IND Sponsor:  Catherine Chappell, MD, MS  
 
Protocol Chair:  Catherine Chappell, MD, MS  
 
Sample Size:  10 women  and their infan ts (participants who do not 
complete treatment or report less than 85% adherence will 
be replaced)  
 
Study Population:  Pregnant women diagnosed with chronic hepatitis C 
infection  that are between the ages of 18 and 39 and are 
between 14 + 0 and 22 + 6  weeks  of gestation at S creening 
and infants born to the enrolled participants  
 
Study Site:  UPMC Magee -Womens Hospital, Pittsburgh, PA  
 
Study Design:  Single -site, single -arm pharmacokinetic  study  
 
Study Duration:  Approximately 28  weeks per maternal participant  and one 
year of infant follow up . 
 
Study Medication : Fixed -dose combination tablet of Sofosbuvir 400 mg  and 
Velpatasvir 100 mg  (SOF/VEL ) 
 
Study Regimen:   Participants will take SOF/VEL one table t once daily starting 
between 23 + 0 and 2 5 + 6 weeks of gestat ion for 12 weeks 
total.  
 
PK Sampling:   Systemic exposure of both VEL and SOF (SOF and inactive 
metabolite GS -331007)  and intracellular SOF  (GS-461203 ) 
will be assessed by intensive pharmacokinetic sampling at 3 
time points:   
1) 3 weeks  7 days after first do se (intensive);  
2) 6 weeks  7 days after first dose (sparse) ;  
  2)  9 weeks  7 days after first dose  (intensive) . 
 
 
 
 
SOF/VEL in Pregnancy, Version 5.0 8 December 2  , 2020  
  
Primary Objective:  
• To compare the plasma pharmacokinetic (PK) parameters of SOF/VEL  
administered in pregnancy  to available data from nonpre gnant women . 
 
Primary Endpoint:  
• Systemic plasma  exposures  of both VEL and SOF  (SOF  and GS-331007)  will 
be assessed:  
 3 weeks  7 days after first dose (intensive);  
 6 weeks  7 days after first dose (sparse) ; 
 9 weeks  7 days after first dose  (intensive) . 
 
Secondary Objective s: 
 
• To compare the intracellular concentrations of SOF (GS -461203) to available 
data from nonpregnant women.  
 
• To compare the protein binding (free -fraction) of VEL in pregnant women vs. 
available data in non -pregnant women.  
 
• To determine the rate of sustained viral response  (SVR12) , defined by 
undetectable hepatitis C virus twelve  weeks  after completion of SOF/VEL  
treatment for 12 weeks during pregnancy.  
 
• To evaluate the safety for the mother and for the neonate of hepatitis C 
treatment wi th SOF/VEL  during pregnancy.  
 
 
Secondary Endpoints:  
 
• Intracellular SOF (GS -461203) concentrations will be a ssessed at:  
 3 weeks  7 days after first dose;  
 6 weeks  7 days after first dose;  
 9 weeks  7 days after first dose.  
 
• Free-fraction of VEL (protein binding)  will be assessed at:  
 3 weeks  7 days after first dose;  
 9 weeks  7 days after first dose.  
 
• Sustained Viral Response ( SVR12 ) 
• HCV RNA viral load will be assessed at 12 weeks after 
completion of SOF/VEL  treatment.  An undetectable viral load 
will be considered a SVR12 . 
 
 
 
SOF/VEL in Pregnancy, Version 5.0 9 December 2  , 2020  
 • Maternal Safety  
• Safety laboratory assessments of blood counts, creatinine, liver 
function, creatinine kina se and lipase will be measured at the 
PK1 and PK2 visit s (approximately 3 weeks and 6 weeks  after 
treatment initiation ). 
• Pregnancy and delivery outcomes collected prospectively  by 
participant interview and medical record review . 
 
 
• Neonate Safety  
• Major malf ormations, defined as structural abnormalities with 
medical, surgical or cosmetic importance ; 
• Weight, length, and head circumference at birth, 8 weeks , 6 
months and 12 months ; 
• HCV RNA viral load at birth  (as available) , 1 to 3 month s, at 6 
months and  then again at 12 months only if negative viral loads 
are not documented at 1 to 3 and 6 months ; 
• Neurodevelopmental assessments  at 6 months and 12 months . 
 
Exploratory Objectives:  
 
• Describe the perspectives of pregnant women with chronic HCV 
infection screening for a trial of antenatal sofosbuvir/velpatasvir 
(SOF/VEL) therapy  
 
Exploratory Endpoint : 
• In depth interviews conducted before enrollment in screened 
participants and after completion of treatment in enrolled 
participants.  
 
  
 
 
SOF/VEL in Pregnancy, Version 5.0 10 December 2  , 2020  
 Table 1: Study Visit Schedule  
 
 Maternal Study Visit  Target windows† 
V1 Screening  14+0 to 22+6 weeks gestation (weeks + days)  
V2* Enrollment  23+0 to 2 5+6 weeks gestation (weeks + days)  
V3 PK1: Intensive  3 weeks  7 days after first dose of SOF/VEL  
V3a^ PK1a, 24hr sample  24 hours  2 hours  
V4 PK2:  Sparse  6 weeks  7 days after first dose of SOF/VEL  
V5 PK3:  Intensive  9 weeks  7 days after first dose of SOF/VEL  
V5a^ PK3a, 24hr sample  24 hours  2 hours  
V6 End of Treatment  Within 7 days of SOF/VEL completion  
Del** Delivery   
V7/iV1  Post treatment  12 weeks ± 4 days  after completion of therapy  
 Infant Study Visit  Infant Age  
Del** Delivery  Newborn  
V7/iV1  Infant Visit 1  8 weeks ± 6 weeks† 
iV2 Infant Visit 2  6 months  ± 2 weeks† 
iV3 Infant Visit 3  12 months ± 2 weeks† 
†These are target windows.  If the participant cannot be seen within these windows then it 
will not be consi dered a protocol deviation .  
*Start SOF/VEL  and continue for 12 weeks  
**The Delivery Visit will occur during admission for participants delivering at Magee -Womens 
Hospital.  Participants who deliver at an outside location will be contacted by phone as clos e 
to delivery as possible to complete the applicable Delivery Visit study procedures (i.e. 
questionnaire, update locator information, update medical history).  All participants, regardless 
of delivery location will undergo a chart review to obtain delivery  outcomes/variables , as long 
as medical records can be obtained/reviewed .  
^Study visit is scheduled 24 hours from dosing at previous visit (V3 and V5); the 24 hour study 
visit and associated procedures must occur prior to dosing that day (V3a and V5a)  
 
  
 
 
SOF/VEL in Pregnancy, Version 5.0 11 December 2  , 2020  
 1 KEY ROLES  
 
1.1 Protocol Identification  
 
Protocol Title:   Phase 1 Pharmacokinetic Trial of 
Sofosbuvir /Velpatasvir  in Pregnant Women 
with Chronic Hepatitis C Virus Infection    
 
Short Title:   Treatment of Chronic Hepatitis C during Pregnancy 
with Sofosbuvir /Velpa tasvir  
 
 
 
1.2 Funders, Sponsor and Monitor Identification  
 
Funding Agencies:  
 
NIH Building Interdisciplinary Research Careers in Women’s Health in Pittsburgh  
 
Gilead Sciences  
 
National Institutes of Health  Eunice Kennedy Shri ver National Institute of Child 
Health & Human Dev elopment   
 
Pennsy lvania Department of Health  
 
 
IND Sponsor:  Catherine Chappell, MD MSc     
 
   
Pharmaceutical Collaborator:  Gilead Sciences  
  
  
  
 
 
SOF/VEL in Pregnancy, Version 5.0 12 December 2  , 2020  
  
1.3 Laboratories  
 
Clinical Laboratory : UPMC Presbyterian Shadyside CPPUH  
 UPMC Clinical Laboratory  Building  
 3477 Euler Way  
 Pittsburgh, PA  15213 USA  
 
Pharmacokinetic Processing:  Magee -Womens Research Institute  
 Laboratory of Dr. Sharon Hillier  
 204 Craft Ave, 5th floor 
 Pittsburgh, PA 15213  
 
Phar macokinetic Assays : University of Colorado  
  Antiviral  Pharmacology Laboratory  
  12850 E Montview Blvd, V20 -C238  
  Aurora, CO  80045   
   
HCV Resistance Testing:   Quest Diagnostics Incorporated  
1901 Sulphur Spring Rd.  
     Baltimore MD 21227  
  
 
 
SOF/VEL in Pregnancy, Version 5.0 13 December 2  , 2020  
  
2 INTRODUCTION  
 
2.1 Chronic Hepatitis C Infection in Pregnancy  
 
A risin g prevalence of hepatitis C virus (HCV) infection has been one of the most 
significant consequences of the opioid epidemic. Injection drug use among 
reproductive -aged persons is now the leading cause of new HCV infections1 and has 
resulted in a dramatic rise in prevalence of HCV among pregnant women2.  From 
2006 to 2012 the rate of HCV among young people increased by 364% in states 
hardest hit by the opioid epidemic such as Kentucky, Tennessee, Pennsylvania and 
West Virginia3.  Chronic HCV leads to liver disease and cirrhosis4 and is the leading 
cause of mortality from a nationally notifiable infection (NNI) in the US, surpassing all 
60 other NNIs combined5. Infants born to women with HCV have a 4 -7% risk of 
perinatal HCV infection6, and are at increased risk for congenital anomalies, low 
birth weight, and neonatal intensive unit (NICU) care2,7,8. HCV -exposed infants also 
have a greater risk of adverse neurologic out comes, including cephalohematoma, 
fetal distress, feeding difficulties, intraventricular hemorrhage, and neonatal seizure9 
although these finds could be confound ed by comorbid substance use. Therefore, it 
is biologically plausible that treatment of HCV during pregnancy could improve both 
pregnancy and neonatal outcomes in addition to prevention of perinatal HCV 
transmission.  
 
HCV cure provides significant health benefits outside of pregnancy. The goal 
of HCV treatment is to render HCV undetectable in the serum, liver tissue and 
mononuclear cells10-12.  Sustained virologic response (SVR12) is defined as the 
absence of detec table HCV RNA in the serum at least 12 weeks after ending 
therapy.  SVR12 has been shown to be a durable predictor of HCV cure when HCV 
RNA is collected for five years or more13,14.  Patients cured of HCV experienc e 
significant health benefits including decreased liver inflammation, slowed and 
reversed progression of liver fibrosis and cirrhosis15.  Additionally, SVR is associated 
with a 70% reduction in the risk of hepatoce llular carcinoma and a 90% reduction in 
the risk of liver -related mortality and liver transplantation16.   Furthermore, treatment 
of persons who use injection drugs can prevent community transmission of HCV, so 
called “treatment as prevention17.” For these reasons, the Infectious Disease Society 
of America (IDSA) treatment guidelines recommend that all HCV -infected persons  
be treated18. Despite these recommendations,  pregnant women are excluded 
because the safety and efficacy of treatment during pregnancy has not been 
established.  
 
Pregnant women are a priority population in HCV elimination efforts.  In 2016, 
the World Health Organization (WHO) adopted the goal to eliminate hepatitis as a 
major public threat by 2030 by reducing hepatitis incidence from 6 -10 to 0.9 million 
cases, and to reduce annual hepatitis deaths from 1.4 to 0.5 million19.  In the 
national response to the WHO goal, the Department of Health and Human Services 
 
 
SOF/VEL in Pregnancy, Version 5.0 14 December 2  , 2020  
 National Viral Action Plan 2017 -2020 specifically includes pregnant women as a 
priority population due to the risk of perinatal HCV transmission20.  Although 
avoidance of certain obstetric procedures, such as amniotomy and invasive fetal 
monitoring, m ay decrease perinatal HCV transmission, evidence is lacking21,22. 
Thus, effective HCV treatment during pregnancy could be the most effective 
intervention to prevent perinatal transmission.  
 
 
2.2 Rationale  
 
Pregnancy i s a critical window of opportunity for HCV screening and 
treatment.  Pregnancy may be the ideal time to provide HCV treatment due to 
enhanced maternal investment in neonatal health outcomes. A meta -analysis of 
adherence to antiretroviral therapy during and after pregnancy showed a statistically 
significant difference in adherence during pregnancy (75.5%) compared to the 
postpartum period (53.0%) 23. In a retrospective cohort study of 369 pregnant 
women who were HCV s eropositive at our institution from 2009 to 2012, 285 (77%) 
were referred to hepatology for postpartum treatment, but only 71 (25%) attended 
the consultation and only 6 (1.6%) were treated in the first year postpartum24. 
Furthermore, in an ongoing study of postpartum HCV treatment with SOF/VEL 
paired with medication -assisted treatment (MAT) at our institution, 6 (50%) of 12 
enrolled participants were lost to follow -up prior to treatment completion25. Thus, 
pregnancy may be the ideal period for enhanced HCV treatment  adherence and 
engagement.   
 
Addressing the knowledge gap: pharmacokinetic and safety studies of new 
antivirals in pregnancy. Significant physiologic changes occur during pregnancy 
that effect drug absorption, distribution, metabolism and excretion, result ing in PK 
changes which may have clinical consequences26. For example, increased renal 
clearance of drugs could result in suboptimal concentrations with standard dosing for 
renally cleared drugs, leading to antivir al resistance or decreased efficacy27. To 
illustrate this, some antiretroviral medications, such a s atazanavir and lopinavir, 
require dose changes during pregn ancy to achieve therapeutic drug concentrations 
in the late second or third trimesters27. Plasma protein concentrations including 
alpha -1 acid glycoprotein and  albumin decrease in pregnancy, potentially influencing 
free drug concentrations; therefore, to comprehensively evaluate the impact of these 
physiologic changes in pregnancy for highly protein bound drugs, assessment of 
both total and free drug concentrati ons is critical.  
 
Preliminary data: Our Phase 1 trial of ledipasvir/sofosbuvir (LDV/SOF) 
treatment in pregnancy has promising preliminary results.  Between June 2017 
and October 2018, 9 pregnant women between 23 -24 weeks’ gestation with chronic 
genotype 1 HCV infection were treated with LDV 90mg - SOF 400mg daily for 12 -
weeks. Three intensive PK visits were performed at 25 -26, 29 -30, and 33 -34 weeks’ 
gestation. Plasma was collected pre -dose, 0.5, 1, 2, 3, 4, 5, 8 and  12 hours post -
dose to measure LDV, SOF an d GS -331007 (the inactive metabolite of SOF) by 
 
 
SOF/VEL in Pregnancy, Version 5.0 15 December 2  , 2020  
 validated HPLC -MS/MS methods28. Of 29 women screened, 20 were excluded due 
to genotype 2 or 3 infection (n=10), ongoing illicit drug use (n=4), declining 
participation (n=3), intention to deliver off -site (n=2), and an APRI score of >1 (n=1). 
All 9 women enrolled were white, with a median age of 31 years. Our published data 
documented that 93% of p regnant women having HCV at our institution are white29.  
Eight women were HCV infected due to intravenous drug use (4 receiving opioid 
pharmacotherapy) and one was perinatally infected. All nine (100%) participants 
were cured and there were no adverse events greater than grade 2 related to 
LDV/SOF30. There were no significant differences found between the PK parameters 
at each gestational age timepoint.   
 
Althou gh there are significant physiologic differences between pregnant and non -
pregnant women, there are minimal differences between the second and third 
trimesters of pregnancy31. For example, the glomerular filtration  rate is increased 
37% in the second trimester and 40% in the third trimester32. Therefore, PK 
parameters were averaged across the three visits and compared between 
participants and non -pregnant women from regulatory trials of LDV/SOF. The 
geometric mean ratios and corresponding 90% confidence intervals are shown in 
Table 1. Similar  LDV and SOF, but lower GS -331007 exposures were observed 
between pregnant and non -pregnant women. All nine participants (100%) were 
cured. There were no adverse events related to LDV/SOF greater  than grade 2. 
One-year follow -up of infants is on -going , and all remain HCV negative.  
 
 
Table 1: Sofosbuvir, GS -331007, and Ledipasvir Exposure in HCV -Infected Pregnant 
women Compared to Non -Pregnant Women  
PK Parameter  
Mean (%CV)  HCV -infected 
Pregnant 
Women  
 (N=8)**  HCV -infected 
Non-Pregnant 
Women 
(N=43)***  %GMR (90%CI)  
SOF AUC tau 
(hr*ng/mL)  1840 (15.2)  2210 (49.9)  92.0 (78.8, 107)  
Cmax (ng/mL)  1290 (29.3)  1640 (47.8)  89.0 (68.6, 115)  
GS-
331007  AUC tau 
(hr*ng/mL)  8930 (12.1)  14800 (29.6)  62.3 (56.4, 
68.7)  
Cmax (ng/mL)  706 (15.0)  1130 (25.9)  63.7 (57.3, 
70.8) 
LDV AUC tau 
(hr*ng/mL)  10500 (34.4)  12100 (46.0)  90.3 (69.6, 117)  
Cmax (ng/mL)  580 (36.2)  644 (41.9)  91.8 (71.2, 118)  
Ctau (ng/mL)  343 (37.6)  433 (54.9)  84.9 (64.0, 113)  
 
 
SOF/VEL in Pregnancy, Version 5.0 16 December 2  , 2020  
 *All data are presented to 3 significant digits. Abbreviations: AUCtau, area u nder the 
concentration -time curve of the dosing interval; Cmax, maximum measured concentration, 
Ctau, concentration at the end of the dosing interval; CI, confidence interval; CV, coefficient 
of variation; GMR, geometric mean ratio.  
**Average of individual  participant PK parameters from all 3 PK visits were used. 1 
participant was excluded from the analysis for suspected dosing errors prior to PK visits.  
*** Non -pregnant women from LDV/SOF Phase 2/3 studies with intensive PK assessments.  
 
In this first stud y of HCV treatment during pregnancy, LDV/SOF was safe and 
effective with similar LDV and SOF PK exposure in pregnancy. Lower inactive 
metabolite (GS -331007) exposure is likely due to increased glomerular filtration rate 
during pregnancy. The results from t he completed study support the safety of 
LDV/SOF which provides additional safety data supporting the use of SOF/VEL in 
the proposed study. Further, this pilot study demonstrated that it is feasible to enroll 
and treat HCV infected pregnant women, but a pa n genotypic regimen is needed. 
Because the PK did not differ by gestation, the proposed study will limit intensive PK 
sampling to a single gestational age as to not overly burden the participants, but 
sparse sampling will occur at other time points during treatment. Although no 
differences in SOF levels were detected when comparing pregnant women to 
historical nonpregnant controls, the inactive metabolite of SOF (GS -331007) was 
reduced over 30% suggesting that additional data are needed to confirm that no 
change in the active metabolite of SOF occurs. Compared with LDV, VEL is more 
highly reliant on the cytochrome P450 enzyme 3A (CYP3A).  CYP3A is upregulated 
in pregnancy, so there is a potential for a greater effect of pregnancy on VEL.  
 
VEL bioavailability  is estimated to be 30 -50% based on animal studies and is not 
influenced by food intake. Notably, VEL requires an acidic environment for 
absorption.  VEL is >99.5% protein bound, is hepatically metabolized by cytochrome 
P450 enzymes (CYP3A4, CYP2B6, and CY P2C8). VEL is primarily eliminated via 
biliary excretion, resulting in a plasma half -life of 15 hours33,34. The bioavailability of 
SOF is >80% and a high fat meal increases SOF exposure by 67 -91%. SOF is 61 -
65% pla sma protein bound, 14% is hepatically metabolized by phosphorylation, and 
80% is renally excreted. As a prodrug, SOF half -life is 0.4 hours, while GS -331007 is 
27 hours.  SOF is administered as a phosphoramidate prodrug of the uridine 
nucleotide analogue G S-331007 monophosphate35. SOF is hydrolyzed by cathepsin 
A and/or carboxyesterase 1 and then phosphorylated by cellular kinases to the 
triphosphate moiety (GS -461203)35,36. GS-461203 is the active form of SOF. GS -
461203 then is dephosphorylated to GS -331007, which is the inactive SOF 
metabolite that is most readily measured in the plasma.  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 17 December 2  , 2020  
 The physiologic changes of pregnancy and the possible PK effects on SOF and VEL 
are shown in Table 1 .    
Given that the magnitude of each physiologic change is hard to predict, the overall 
systemic VEL and SOF exposure cannot be assumed. Further, the plasma 
concentrations of SOF and GS -331007 may not reflect the intracellular 
concentratio ns of the active SOF metabolite (GS -461230).  To address this 
knowledge gap, we will conduct a thorough PK evaluation of VEL and SOF, 
including protein binding and the measurement of the intracellular GS -461230 
concentrations  to offer insights into the phy siologic processes altering the PK of 
these drugs in pregnancy and to determine whether dose adjustment is needed.  
 
 
2.3 SOF/VEL  Fixed Dose Combination  
 
2.3.1  Description  
 
Sofosbuvir is described chemically as (S) -Isopropyl 2 -((S)-(((2R,3R,4R,5R) -5- (2,4-
dioxo -3,4-dihydropyrimidin -1(2H) -yl)-4-fluoro -3-hydroxy -4-methyltetrahydrofuran -2- 
yl)methoxy) -(phenoxy)phosphorylamino)propanoate. It has a molecular formula of 
C22H29FN3O9P and a molecular weight of 529.45. Sofosbuvir is a white to off -white 
crystalline solid with a solubility of ≥2 mg/mL across the pH range of 2 –7.7 at 37C 
and is slightly soluble in water34. 
Velpatasvir  is described chemically as Methyl {(1 R)-2-[(2S,4S)-2-(5-{2- [(2S,5S)-1-
{(2S)-2-[(methoxycarbonyl)amino] -3-methylbutanoyl} -5-methylpyrrolidin -2-yl]- 1,11-
dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2 -d]imidazol -9-yl}-1H-imidazol -2-yl)-4- 
(methoxymethyl)pyrrolidin -1-yl]-2-oxo-1-phenylethyl}carbamate. It has a molecular 
formula of C 49H54N8O8 and a molecular weight of 883.0.  
Each tablet contains 100 mg Velpatasvir  and 400 mg sofosbuvir. The tablets include 
the following inactive ingredients: copovidone, croscarmellose sodium, magnesium 
stearate, and microcrystalline cellulose . The tablets are film -coated with a coating 
material containing the following inactive ingredients: iron oxide red, polyethylene 
glycol, polyvinyl alcohol, talc, and titanium dioxide.  
2.3.2  Mechanism of Action  
 

 
 
SOF/VEL in Pregnancy, Version 5.0 18 December 2  , 2020  
 Velpatasvir  inhibits the HCV NS5A protein and sof osbuvir inhibits HCV NS5B RNA -
dependent RNA polymerase, which are essential for viral replication . Sofosbuvir is a 
nucleotid e prodrug that is metabolized t o the pharmacologically active metabolite GS -
461203, which is incorporated into HCV RNA by NS5B polym erase where it acts as a 
chain terminator .  
 
Velpatasvir  has potent pangenotypic antiviral activity against HCV genotypes  1a, 1b, 
2a, 2b, 3a, 4a, 4d, 5a, 6a, and 6e with EC50 values of 0.014, 0.016, 0.016, 0.006, 
0.004, 0.009, 0.004, 0.054, 0.009, and 0.13 0 respectively .  Sofosbuvir similarly 
demonstrated pangenotypic antiviral activity, with EC50 values against HCV 
genotypes 1a, 1b, 2a, 2b, 3a, 4a, 5a, and 6a, of 40, 110, 50, 15, 50, 40, 15, and 14 
nmol/L, respectively in HCV replicon assays .  SOF/VEL  has potent activity against 
HCV genotype 1 , 2, 3, 4, 5, and 634.  
 
2.4 Clinical Studies  
 
2.4.1  Clinical Studies of Sofosbuvir/ Velpatasvir  for the Treatment of HCV  
 
Approximately 1035  participants  without cirrhosis or with compensated cirrhosis  have 
been enrolled in several  multicenter,  Phase 3 trials to assess the  efficacy of treatment 
with SOF/VEL  for 12 weeks  in patients with genotype s 1, 2, 3, 4, 5, and 6  chronic 
hepatitis C virus infect ion, ASTRAL -1, ASTRAL -2 and ASTRAL -3 (Table 2 ).  ASTRAL -
1 was a randomized, double -blind, placebo -controlled trial that evaluated  
12 weeks of treatment with EPCLUSA compared with 12 weeks of placebo in 
participants with genotype 1, 2, 4, 5, or 6 HCV infect ion without cirrhosis or with 
compensated cirrhosis37.  ASTRAL -2 was a randomized, open -label trial that 
evaluated 12 weeks of treatment with EPCLUSA compared with 12 weeks of 
treatment with SOF with ribavirin in s ubjects with genotype 2 HCV infection38.  
ASTRAL -3 was a randomized, open -label trial that evaluated 12 weeks of treatment 
with EPCLUSA compared with 24 weeks of treatment with SOF with ribavirin in 
subjects with g enotype 3 HCV infection38.  Approximately 40% (over 400) of the 
participants in these trials were women. There were no on -treatment virologic failures 
reported, however 13 (1%) participants experience virologic fai lure after treatment or 
relapse, most commonly among participants with genotype 3 infection.   Another 12 
(5%) participants failed to achieve SVR due to non -adherence, due to adverse 
reaction (n=2) or another reason for treatment interruption (Table 2).   
 
Table 2:  Virologic outcome  of a 12-week course of SOF/VEL  for the treatment of HCV 
infection in participants without cirrhosis or with compensated cirrhosis  from ASTRAL -
1, ASTRAL -2, and ASTRAL -3 
Geno-
type N Total  N 
SVR12  Rate of 
SVR12  On-Treatment 
Virolo gic Failure  After -Treatment 
Virologic Failure  Other  
1 328 323 98% 0 2 (1%)  3 (1%)  
2 238 237 100%  0 0 1(<1%)  
3 277 264 95% 0 11(4%)  2 (1%)  
 
 
SOF/VEL in Pregnancy, Version 5.0 19 December 2  , 2020  
 4 116 116 100%  0 0 0 
5 35 34 97% 0 0 1 (1%)  
6 41 41 100%  0 0 0 
 
 
 
Safety    
The safety and tolerability of SOF/V EL has been evaluated within the setting of Phase 
3 clinical trials.  Overall, SOF/VEL  was well tolerated by patients with chronic HCV 
infection (N= 1035 ) with only 2 participants permanently discontin ing  treatment due to 
adverse events was 0.2%.  The m ost common adverse reactions (adverse events 
assessed as causally related by the investigator and at least 10%) were headache 
and fatigue.  Adverse reactions, all grades, observed in greater than or equal to 5% 
of participants receiving 12 weeks of treatme nt with SOF/VEL in ASTRAL -1 include 
headache (22%), fatigue (15%), nausea (9%), asthenia (5%), and insomnia (5%). Of 
subjects receiving 12 weeks of treatment with SOF/VEL  79% had an adverse reaction 
of mild severity (Grade 1). With the exception of asthen ia, each of these adverse 
reactions occurred at a similar frequency or more frequently in participants treated 
with placebo compared to participants treated with SOF/VEL (asthenia: 3% versus 5% 
for the placebo and SOF/VEL groups, respectively).  The advers e reactions observed 
in participants treated with SOF/VEL in ASTRAL -2 and ASTRAL -3 were consistent 
with those observed in ASTRAL -1. Irritability was also observed in greater than or 
equal to 5% of participants  treated with  SOF/VEL  in ASTRAL -3.  In the ASTR AL-1 
study, rash occurred in 2% of participants  treated with SOF/VEL  and in 1% of 
participants  taking  placebo. No serious adverse reactions of rash occurred and all 
rashes were mild or moderate in severity.   In the ASTRAL -1 study, depressed mood 
occurred i n 1% of participants treated with SOF/VEL  and was not reported by any 
placebo participants . No serious adverse reactions of depressed mood occurred and 
all events were mild or moderate in severity34.   
Hepatitis B virus (HBV) reactivation has been reported in HCV/HBV coinfected 
patients who were undergoing or had completed treatment with HCV direct acting 
antivirals, and who were not receiving HBV antiviral therapy. Some cases  have 
resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported 
in patients who are HBsAg positive and also in patients with serologic evidence of 
resolved HBV infection (i.e., HBsAg negative and anti -HBc positive).  We will 
exclude participants that are anti -HBc positive for this reason.   Additionally, 
postmarketing cases of symptomatic bradycardia and cases requiring pacemaker 
intervention have been reported when amiodarone is coadministered with a 
sofosbuvir -containing regim en. Additionally a fatal cardiac arrest occurred in a 
patient taking amiodarone that was co -administered with sofosbuvir.  For this 
reason,  we will exclude participants who are taking amiodarone34.   
Laboratory abnormalities:  
 
 
SOF/VEL in Pregnancy, Version 5.0 20 December 2  , 2020  
 Lipase Elevations: In ASTRAL -1, isolated, asymptomatic lipase elevations of greater 
than 3 times the upper limit of normal were observed in 3% and 1% of participants 
treated with SOF/VEL and placeb o for 12 weeks, respectively; and in 6% and 3% of 
participants treated with SOF/VEL in ASTRAL -2 and ASTRAL -3, respectively34.  
Creatine Kinase: In ASTRAL -1, isolated, asympto matic creatine kinase elevations 
greater than or equal to 10 times the upper limit of normal were reported in 1% and 
0% of participants treated with SOF/VEL and placebo for 12 weeks, respectively; 
and in 2% and 1% of participants treated  with SOF/VEL in AS TRAL -2 and ASTRAL -
3, respectively.  
2.4.2  Animal Studies of Sofosbuvir and Velpatasvir  During Pregnancy  
 
There are no adequate studies of SOF/VEL  in pregnant women.  In animal 
reproduction studies, no evidence of adverse developmental outcomes was observed 
with t he components sofosbuvir or velpatasvir at exposures greater than those in 
humans at the recommended human dose. During organogenesis in the mouse, rat, 
and rabbit, systemic exposures (AUC) to velpatasvir were approximately 31 (mice), 6 
(rats), and 0.4 (ra bbits) times the exposure in humans at the recommended human 
dose , while exposures to the predominant circulating metabolite of sofosbuvir (GS -
331007) were approximately 4 (rats) and  10 (rabbits) times the exposure in humans 
at the  recommended human dose34.  
 
Velpatasvir : Velpatasvir was administered orally to pregnant mice (up to  
1000 mg/kg/day), rats (up to 200 mg/kg/day) and rabbits (up to 300 mg/kg/day) on 
gestation days 6  to 15, 6 to 17, and 7 to 20, respectively, and also to rats (oral doses 
up to 200 mg/kg) on gestation day 6 to lactation/post -partum day 20. No significant 
effects on embryo -fetal (mice, rats, and rabbits) or pre/postnatal (rats) development 
were observed  at the highest doses tested. The systemic exposures (AUC) of 
velpatasvir during gestation were approximately 31 (mice), 6 (rats), and 0.4 (rabbits) 
times the exposure in humans at the recommended human dose.  
 
Sofosbuvir: Sofosbuvir was administered orally  to pregnant rats (up to 500 mg/kg/day) 
and rabbits (up to 300 mg/kg/day) on gestation days 6 to 18 and 6 to 19, respectively, 
and also to rats (oral doses up to 500 mg/kg/day) on gestation day 6 to lactation/post - 
partum day 20. No significant effects on embryo -fetal (rats and rabbits) or 
pre/postnatal (rats) development were observed at the highest doses tested. The 
systemic exposures (AUC) of the predominant circulating metabolite of sofosbuvir 
(GS-331007) during gestation were approximately 4 (rats) and  10 (rabbits) times the 
exposure in humans at the RHD.  
 
2.5 Rationale for Study Design  
 
There is currently no experience with SOF/VEL  in pregnant women, although based 
on the animal model data submitted to the FDA  there were no effects on fetal 
development obs erved in mice, rats and rabbits with doses higher than those given 
 
 
SOF/VEL in Pregnancy, Version 5.0 21 December 2  , 2020  
 for treatment of hepatitis C in humans.  Also,  there is reassuring data from our prior 
study of treatment with LDV/SOF.  Unfortunately, LDV/SOF is not approved for 
treatment of HCV genotype s 2 and 3 and therefore a pan -genotypic regimen in 
pregnancy is needed. Before larger scale treatment studies can be undertaken, it will 
be necessary to assess whether the pharmacokinetics of the drugs are similar in 
pregnant and nonpregnant women, and whe ther treatment  response  is similar to that 
observed in nonpregnant women, given the higher viral loads observed during 
pregnancy. This study is designed to address those knowledge gaps. We propose a 
single -arm, single -center, open label Phase 1 study of a 12-week course of SOF/VEL 
in 10 HCV -infected pregnant women.  Treatment will be initiated during the second 
trimester, reducing the risk of SOF/VEL exposure during organogenesis and ensuring 
treatment completion by delivery, minimizing the risk of perinata l transmission.   
Additionally, this will allow adequate time for treatment course completion by delivery.   
 
The study will be comp leted in 10 or 11  visits  (7 maternal visits , delivery visit  and 3 
infant visits)  which should easily align with prenatal  and postpartum visits (Table  1). 
We plan to screen patients between 14+0 and 22+6 weeks of gestation confirmed by 
ultrasoun d by the time of their Enrollment visit who are known to  have chronic HCV 
infection .  A HCV RNA level to confirm the patient is actively  infected with HCV as well 
as an HCV genotype  (when not already available within 3 months of screening visit)  
will be o btained .  A full laboratory evaluation of liver function includ ing CBC, PT/INR, 
hepatic panel,  creatinine , creatinine kinase and lipase  will be obtained, to evaluate for 
renal failure and decompensated cirrhosis.   A Hepatitis B Virus (HBV) panel will be 
performed to test all patients for evidence of current or prior HBV infection before 
initiation of HCV treatment.   Medical history and demographic information will also be 
collected at screening.  If the following inclusion and exclusion criteria are met, th en 
the patient will be enrolled into the study between 23+0 and 2 5+6 weeks’ gestation 
and initiated on  a 12 week course of SOF/VEL . 
3 OBJECTIVES  
 
3.1 Primary Objective  
 
1. To compare the plasma pharmacokinetic  (PK) parameters of SOF/VEL  
administered during pregnan cy to those  of nonpregnant women . 
 
3.2 Secondary Objectives  
 
1. To compare the intracellular concentrations of SOF ( GS-461203) during 
pregnancy to  available data from  nonpregnant women.  
 
 
2. To compare the protein binding (free fraction) of VEL in pregnant women to  
available data from nonpregnant women.  
 
 
SOF/VEL in Pregnancy, Version 5.0 22 December 2  , 2020  
 3. To determine the rate of sustained viral response (SVR12), defined by 
undetectable hepatitis C virus twelve weeks after completion of SOF/VEL 
treatment for 12 weeks during pregnancy.  
 
4. To evaluate the safety for the mother  and for the neonat e of hepatitis C 
treatment with SOF/VEL  during pregnancy.  
 
3.3 Exploratory Objective  
 
1.  To describe the perspectives of pregnant women with chronic HCV infection 
screening for a trial of antenatal sofosbuvir/velpatasvir (SOF/VEL) therapy  
4 STUDY DESIGN  
 
4.1 Identification of Study Design  
 
This is a single -site, open label , single -arm Phase 1  trial.  
 
4.2 Summary of Major Endpoints  
 
Primary Endpoint:  
 
• Systemic PK  
- Systemic  exposure  of both VEL and SOF  will be assessed a t three  time 
points:  
1) 3 weeks a fter treatment initiation  (intensive sampling) ; 
2) 6 weeks after treatment initiation (sparse sampling) ; 
3) 9 weeks after treatment initiation (intensive sampling) . 
 
Secondary Endpoints:  
 
• Seconda ry PK endpoints:  
 Intracellular concentrations of GS -461203 from dr ied blood spots 
and peripheral blood mononuclear cells (PBMCs)  will be 
assessed at:  
• 3 weeks  7 days after first dose;  
• 6 weeks  7 days after first dose;  
• 9 weeks  7 days after first dose.  
 
 Free-fraction of VEL (protein -binding)  will be assessed at:  
• 3 weeks  7 days after first dose;  
• 9 weeks  7 days after first dose.  
 
• Sustained Viral Response ( SVR12 ) 
 
 
SOF/VEL in Pregnancy, Version 5.0 23 December 2  , 2020  
 • HCV RNA viral load will be assessed at 12 weeks after 
SOF/VEL  treatment completion. An undetectable viral load will 
be considered a SVR12 . 
 
• Maternal Safety  
• Safety laborato ry assessments of blood counts , creatinine,  liver 
function , creatinine kinase a nd lipase  will be measured at the 
PK1 and PK2 visit ( 3 and 6 weeks after initiation of SOF/VEL ).  
• Pregnancy and delivery outcomes collected prospectively  by 
participant interview  and medical record review.  
 
• Neonate Safety  
• Major malformations, defined as st ructural abnormalities with 
medical, surgical or cosmetic importance  
• Weight, length, and head circumference at birth, 8 weeks , six 
months and 12 months  
• HCV RNA will be assessed at birth ( as available ), 1-3 months  
and 6 months , and  then again at 12 months only if detectable 
viral loads are documented in either of the two previous viral 
load assessments  
• Neonatal development assessed at 6 months and 12 months  
 
Exploratory Endpoint : 
 
• In depth interviews conducted before enrollment in screened 
participants and after completion of treatment in enrolled 
partic ipants  
 
 
4.3 Description of Study Population  
 
The study population will include 10 pregnant women between the ages of  18-39 years 
old (inclusive) at Screening who are chronically infected with Hepatitis C virus, 
genotype 1 , 2, 3, 4, 5 or 6  (or any combination of genotypes) , as described in Sections 
5.2 and 5.3  and infants born to the enrolled participants  
 
4.4 Time to Complete Accrual  
 
The approximate time to complete study enrollment is expected to be  12 months .  
 
4.5 Expected Duration of Participation  
 
The expected duration for maternal participants is approximately 24 weeks, not 
including the screening window .  Infants will be followed for at least a full year after 
birth; therefore mother -child pairs will be enroll ed for approximately one year and 4 
 
 
SOF/VEL in Pregnancy, Version 5.0 24 December 2  , 2020  
 months . Maternal study d ata will be collected  from the participant and/or her medical 
records  through  the Post Treatment  Visit (V7 ).  Maternal p articipants who have AEs 
at the Post Treatment  Visit (V7 ) that are clinicall y significant or related to study 
product /participation  and have not resolved or stabilized will be followed beyond V7 
until a clinically acceptable resolution of the AE(s) is confirmed and documented.  
Similar ly, infant study data will be collected through  the 12 month follow -up visit ( iV3).  
Infants  who have AEs at the iV3 visit that are clinically significant or related to study 
product/participation and have not resolved or stabi lized will be followed beyond iV3  
until a clinically acceptable resolution /stabilization  of the AE(s) is confirmed and 
documented.   
 
5 STUDY POPULATION  
 
5.1 Selection of the Study Population  
 
The inclusion and exclusion criteria in Sections 5.2 and 5.3 will be utilized to ensure 
the appropriate selection of study participants.  
 
5.1.1  Recruitm ent 
 
There are over 10,000 deliveries at M agee -Womens Hospital  (MWH) per year and it 
is estimated that approximately 1% of women who deliver are actively infected with 
HCV.  HCV -infected pregnant women will be recruited  from MWH  and antenatal 
clinics, opiate substitution therapy clinics and recovery programs in Pittsburgh  and 
surrounding areas .    
 
Recruitment will be primarily  targeted from the MWH Pregnancy Recovery Center, 
which was established in 2014 to provide concurrent treatment for opiate 
dependenc e (buprenorphine)  with prenatal care, which has an estimated retention 
rate of 90% for weekly opiate substitution and prenatal visits.  There are 
approximately 120 opiate addicted pregnant women who received prenatal care at 
the Pregnancy Recovery Center p er year.  The prevalence of HCV infection in this 
Center is approximately 60%.  Recruitment will also be targeted at the Magee -
Women s Hospital ambulatory  clinic and associated  clinics that deliver at Magee -
Womens Hospital.  In order to engage HCV -infected women in recovery, but not yet 
engaged in prenatal care, we may also recruit patients from local opiate substitution 
therapy clinics and recover y progra ms that treat pregnant women .   
 
Recruitment may also include  women who are not receiving care at Ma gee-Womens 
Hospital through referrals from health care providers .  These women must be  willing 
to travel to Pittsburgh to complete the study visits  but may deliver at an outside 
hospital as information from delivery may be review ed after obtaining a signed  
medical record release .   
 
 
 
SOF/VEL in Pregnancy, Version 5.0 25 December 2  , 2020  
 Recruitment materials  will be approved by the University of Pittsburgh Institutional 
Review Board prior to use.  
 
5.1.2  Retention  
 
The importance of retention will be stressed to the participant at each visit as part of 
protocol adhere nce counseling.  Once a participant is  enrolled , the study staff will 
make every effort to retain the participants in follow -up to minimize possible bias 
associated  with loss -to-follow -up. Any participant that discontinues the study before 
the PK3 visit is  completed or reports missing more than 1 dose per week averaged 
over the duration of the study will be replaced by recruiting another participant into the 
study.  We anticipate  needing to replace no more than  one participant.  
 
5.2 Inclusion Criteria  
 
Women m ust meet all of the following criteria to be eligible for inclusion in the study. 
Any exclusionary laboratory values can be repeated at a later date within the 
Screening window.  If the repeated laboratory values meet inclusion criteria then the 
participan t can be enrolled. If there is concern that the participant’s health status has 
changed between the screening visit and the enrollment visit or if there is a clinical 
concern by the study investigators, the screening laboratories can be repeated prior 
to enrollment.   
 
1) Age 18  through 39  years (inclusive) at S creening  
 
2) Able and willing to provide written informed consent and take part in the 
study procedures  
 
3) Able and willing to provid e adequate locator information  
 
4) Chronic HCV  (for at least 6 months prior t o screening) by participant report  
 
5) Detectable HCV RNA viral load at Screening  
 
6) Desired pregnancy at 23 + 0 to 2 5 + 6 weeks’ gestation  at Enrollment  with 
gestational dating confirmed by ultrasound  
 
7) Singleton gestation with no known fetal abnormalities  
 
8) Documented negative Hepatitis B testing for current infection (negative 
HBsAg test) or previous infection (negative anti -HB Core) performed at the 
screening visit  
 
9) Negative HIV testing at the screening visit  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 26 December 2  , 2020  
 10) Per participant report at Screening and Enrollment, agrees not to participate 
in other r esearch studies involving   investigational drugs or medical devices  
for the duration of study participation  
 
 
 
5.3 Exclusion Criteria  
 
Women who meet a ny of the following criteria will be excluded from the study:  
 
1) Participant report of any of the following  at Screening or Enrollment : 
a. Previous treatment for Hepatitis C virus  with sofosbuvir or a NS5A 
inhibitor  
b. Use of any medications contraindicated with concurrent use of 
velpatasvir  or sofo sbuvir according to the most current EPCLUSA  
package insert34 
c. Plans to relocate away from the study site area in the next 1 year  and 
4 mo nths and un able/unwilling to return for study visits  
d. Current sexual partner is known to be infected with HIV or Hepatitis B 
virus  
e. History of cirrhosis documented or reporte d by previous liver biopsy or 
liver imaging tests  
 
2) Reports participating in any othe r research study involving investigational 
drugs or  medi cal devices  within  60 days or less prior to E nrollment  
 
3) Clinically significant  and habitual  non-therapeutic drug abuse, not including 
marijuana , as determined by Protocol Chair  
 
4) At Screening or Enroll ment, a s determined by the Protocol Chair , any 
significant uncontrolled active or chronic cardiovascular, renal, liver  (such as 
evidence of decompensated cirrhosis by ascites, encephalopathy, or variceal 
hemorrhage) , hematologic, neurologic, gastrointestin al, psychiatric, 
endocrine, respiratory, immunologic disorder or infectious disease (other than 
Hepatitis C)  
 
5) Has a high risk of preterm birth defined as a history of spontaneous preterm 
birth at  less than  34 weeks of gestation or a shortened cervical leng th of 
less than 20 millimeters   
 
6) Has any of the following laboratory abnormalities at Screening:  
a. Aspartate aminotransferase (AST) or alanine transaminase (ALT) 
greater than 10 times the upper limited of normal  
b. Hemoglobin less than 9 g/dL  
c. Platelet count l ess than 90,000 per mm3 
d. International normalized ratio (INR) > 1.5   
 
 
SOF/VEL in Pregnancy, Version 5.0 27 December 2  , 2020  
 e. Creatinine greater than 1. 4  
 
 
7) Has any other condition that, in the opinion of the IoR/designee, would 
preclude informed consent, make study participation unsafe, complicate 
interpretation  of study outcome data, or otherwise interfere with achieving 
study objectives.  
 
6 STUDY MEDICATION  
 
6.1 Regimen  
 
Each participant will take a 12 week course of SOF/VEL  one tablet  by mouth , once 
daily.   
 
6.2 Administration  
 
Study medication will be dispensed at Enr ollment, PK1,  PK2, and PK 3 visits in the 
quantities sufficien t to have one dose per day until the next scheduled visit with 3 extra 
doses .  Tablets will be packaged by the Investigational Pharmacist/ Pharmacist of 
Record (PoR) /designee  in the pharmacy at Ma gee-Womens Hospital .   Participants 
will be encouraged to use an IRB approved, secure mechanism to capture a 
photo/video of study medication administration   to assist with keeping track of when 
participants took their doses.  This process  will document the date and time of study 
medication administration and can be submitted electronically  anytime throughout 
study participation or can be reviewed at a study visit.  Participants will also be gi ven 
a paper log to record the time of their dose  and will be asked to return the log at the 
next study visit .  The timing of each dose will be reviewed by the research team at 
each visit.  Any discrepancies will be noted.  
 
Each participant will be given  instructions on timing of the dose, what to do if a dose 
is missed and how to store the medication.  If a dose is missed, the  participant  should 
take the dose as soon as it is remembered , but only one dose per day .  Participants 
will be instructed to take t he medication each day at the same time , preferably early 
in the morning .  SOF/VE L can be t aken  with or without food.  Additionally, participan ts 
will be given adherence tips, such as setting an alarm on their phone, linking 
medication time to another dail y activity, etc. Participants will be instructed to bring 
any unused medication to the next visit and to specifically remember to bring the 
morning dose to the PK1  and PK3 Visits  rather than take it at home .  Participants will 
be instructed to call the stu dy staff immediately if they run out of medication or if they 
lose the study medication.  In this case, all possible efforts will be made to get the 
participant study medication as soon as possible.  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 28 December 2  , 2020  
 6.3 Supply and Accountability  
 
6.3.1  Supply  
 
Gilead Sciences will supply the study medication that is manufactured under Good 
Manufacturing Practices as FDA approved bulk product.  The product will be shipped 
to UPMC Magee Womens Hospital Pharmacy’s PoR.  Study  medication will be 
repackaged and labeled prior to dispen sation according to protocol guidelines.  
 
6.3.2  Storage and Dispensing  
SOF/VEL  should be stored at room temperature below 30°C  within the main pharmacy  
at Magee -Womens Hospital34. The PoR /designee  will maintain documentation of 
temperature in the area where the study medication  is stored. Study medications will 
be dispensed from the pharmacy in a small bottle containing  a quantity sufficient  until 
the next study visit  with a bottle of three additional doses  in the case of a lost dose or 
missed study visit .  Study medications will be dispensed from the pharmacy only  upon 
receipt of a written prescription and/or a signed study drug order form from an 
authorized prescriber .  The study m edication  will be dispensed to the study  staff, then 
subsequently provide d directly to the study participant  in the research clinic .  
 
6.3.3  Accountability  
 
The PoR/designee  will maintain complete  accountability  records of all study SOF/VEL  
received and dispense d. All available unused study medication s will be returned to 
Gilead Sciences or destroyed as instructed by Gilead after the study is complete.  
 
6.3.4  Retrieval of Study Medication  
 
The participants will be instructed to return any unused medication  at each  visit. If the 
participant fails to return unused medication at a scheduled visit, reasonable attempts  
will be made and documented to obtain the unused medication  from the participant 
(i.e. at an unscheduled visit). Unused medication  will be accounted for by t he clinician, 
documented in the participant’s research reco rd and then returned to the PoR  and 
accounted for per pharmacy policy .  
 
6.4 Concomitant Medications  
 
Enrolled study participants may use  non-prohibited  concomitant medications during 
study participat ion. All concomitant medications reported throughout the course of the 
study will be recorded on case report forms designated for that purpose. All 
prescription medications, over -the-counter preparations, vitamins, nutritional 
supplements, and herbal prepa rations will be recorded on forms for concomitant 
medications. Participants who are  using medication s that are contraindicated for 
concomitant use with velpatasvir  and sofosbuvir as described in the package insert  
will be excluded from participation .39 Each reported concomitant m edication will be 
reviewed to ensure the participant is not using prohibited medications (i.e. St. John’s 
 
 
SOF/VEL in Pregnancy, Version 5.0 29 December 2  , 2020  
 wort, carbamazepine ) as referenced in the EPCLUSA package insert . At each visit , 
participants will be asked if they have initiated any new medications  or changed any 
reported medications.  If the participant reports using acid suppressing medications , 
specific dosing instructions will be reviewed regarding correct timing  of acid 
suppressing medication  use according to the EPCLUSA package insert.   
7 STUDY  PROCEDURES  
 
An overview of the study visit and evaluations schedule is presented in  Appendix 1 . 
Any clinical or laboratory information collected as a part of the participant’s routine 
clinical care occurring on the same day as the study visit does not nee d to be repeated 
and can be collected from the participant’s medical record.   
 
In the unlikely event of interruptions in study procedures (i.e. from severe weather or 
pandemics like COVID -19), study s taff will refe r to a written HIP2 Mitigation Plan for 
direction in handling study visits and procedures .  The Mitigation Plan outlines tiers or 
severities of interruptions and provides  guidance for continuation of research 
activities , namely ensuring participants can complete 12 weeks of study medication . 
The Mitigation Plan will be  submitted to the IRB so they are aware of the plan for 
unexpected  disruptions in this study.   
 
7.1 Pre-screening  
 
Study staff will pre -screen records to identify potential participants by evaluating 
minimum criteria (i.e. age, gestatio n age, Hep atitis C status).  Healthcare providers  
will be told about  the study and will be asked to provide an IRB approved ad/ written 
material to potential participants or will assess interest.  If the participant agrees, 
research staff can provide additi onal information by reviewing an IRB approved 
screening script, which will include a brief overview of the study and minimum eligibility 
questions.  Women who are interested and qualify based on the screening script may 
schedule a Screening Visit.  Process  information (e.g., number of potential participants 
contacted, number presumptively eligible) may be recorded and stored at the study 
site in the absence of written informed consent from potential participants, provided 
the information is collected in suc h a manner that it cannot be linked to participant 
identifiers. Procedures and documentation will comply with the University of Pittsburgh 
IRB requirements. IRB approved materials (i.e. ads, flyers  videos, and social media 
posts)  may also be used (i.e. hun g throughout the hospital; displayed on electronic 
boards; emailed to providers or appropriate support or community groups).  
 
7.2 Visit 1 - Screening (V1) 
 
Screening can take place anytime with in the screening gestational age window (14+0 
to 22+6 weeks  with ges tational age being determined by available clinical information 
at the screening visit  with confirmation of gestational age by ultrasound prior to 
enrollment ). The gestational age must be confirmed by an ultrasound prior to 
enrollment.   If an ultrasound ha s not been performed yet, then an ultrasound is 
 
 
SOF/VEL in Pregnancy, Version 5.0 30 December 2  , 2020  
 performed as part of routine obstetric care at 20 weeks’ gestation and prior to 
enrollment. The study team will assist the participant in scheduling an ultrasound as 
part routine obstetric care prior to en rollment if the participant does not have one 
already.  Multiple visits may be conducted to complete all required screening 
procedures , if necessary.  Written informed consent will be obtained before any 
screening procedures are initiated.  Participants will  be encouraged to speak with their 
primary care provider to determine whether to initiate hepatitis C treatment during 
pregnancy before deciding whether to participate in the study.   Participants who do 
not meet the eligibility criteria  during the screenin g process  will be discontinued once 
ineligibility is determined. Any exclusionary laboratory values can be repeated at a 
later date within the screening window.  If the repeated laboratory values meet 
inclusion criteria then the participant can be enrolled . If there is concern that the 
participant’s health status has changed between the screening and the enrollment visit 
or if there is concern by the study investigators, the screening laboratories can be 
repeated prior to enrollment.  
 
Table 3: Screening Vis it (V1) 
Visit 1 - Screening Visit  
Component  Procedures  
Administrative and Regulatory  
 • Review and obtain written informed  consent  
• ICF Comprehension Assessment  
• Assign participant ID (PTID)  
• Sign appropriate medical record releases (i.e. to obtain records fro m 
prenatal care ; outside records as necessary)  
• Collect locator information  
• Collect demographic information  
• Visit Questionnaire  
• In-depth Interview (IDI) ** 
• Assess  eligibility  
• Provide reimbursement for study visit  
• Schedule next visit  
Clinical  • Collect  medica l history  & review and print medical/ prenatal records  
including documentation of chronic Hepatitis C  
• Review and obtain documentation of previous liver biopsy or liver 
imaging , if applicable   
• Collect concomitant medications  
• Pre/post -test HIV counseling , as applicable  
• Perform full physical  examination  
• Assess fetal heart tones  
• Confirm gestational dating (by available clinical information but must 
be confirmed by ultrasound prior to enrollment)  
Laboratory  • Collect blood  
• Complete blood count (CBC) with differ ential and platelets  
• Creatinine  
• HIV-1 serology  
• Hepatitis B Virus testing (HBsAg, anti -HBc, Anti -HBs)  
• Coagulation ( PT/INR) 
• HCV RNA viral load  
• HCV genotype *  
• Hepatic function panel (AST, ALT, albumin, total and direct 
bilirubin, and alkaline phosphatase)  
• Lipase  
• Creatin ine kinase  
 
 
SOF/VEL in Pregnancy, Version 5.0 31 December 2  , 2020  
 * HCV genotype testing will be performed as needed.  If a result from routine care testing is available from within the past 3 
months prior to the screening visit then additional genotype testing does not need to be performed.   
**May be performed at the screening visit or  any time prior to enrollment  
7.3 Visit 2 - Enrollment (V2 ) 
 
The following procedures will occur at the Enrollment visit (V2).  During the 
enrollment visit the participant will be given instructions on taking the study 
medication.  
 
Table 4: Enrollment  (V2) 
Enrollment Visit - Visit 2  (V2) 
Component  Procedures  
Administrative and Regulatory  
 • Confirm eligibility  
• Review/update locator  information  
• Visit Questionnaire  
• Provide reimbursement for study visit  
• Schedule next visit  
Behavioral  • Provide counseling  
• Protocol adherence  
• Study medication  use/adherence  
Clinical  • Review/update medical history  
• Review/update concomitant medications  
• Document pre -existing conditions  
• Perform  full physical examination  
• Assess fetal heart tones  
• Provid e Screening test results  and perform post-test HIV counseling , 
as applicable  
Medications  • Participants will receive study medication ( supply enough until next 
visit plus a bottle with 3 extra doses)  
• Participants will receive instructions for daily use a nd for PK visits  
• Participants will receive medication adherence log  and/or be instructed 
on use of photo/video capture of daily dosing  
Laboratory  • Collect blood  
- HCV RNA viral load  
7.4 Follow -up Visits  
7.4.1  Visit  3 to 5 (PK 1 , PK2 and PK3) 
 
The PK1, PK2, and PK 3 visits will occur 3 , 6 and 9 weeks (+/ - 7 days), respectively, 
after initiating SOF/VEL.  The PK visit s will be scheduled as early  as possible within 
visit window to allow for visits that require  rescheduling . 
 
Participants will be asked to return the day a fter V3 and V5 for a 24 hour + 2 hour 
PK visit.  These visits will be labeled as V3a and V5a.  The participant will be 
counseled not to take their dose of study medication until after V3a and V5a 
procedures.  In the event that the participant is unable to be seen in the window 
period (24 hours + 2 hours), the visit and study procedures will still be completed as 
long as the participant has not taken their dose for the day.  Assistance with 
transportation or overnight accommodations will be offered as necess ary to  attempt 
to increase compliance with these visits/window periods.  
 
 
SOF/VEL in Pregnancy, Version 5.0 32 December 2  , 2020  
 Table  5: Follow -up Visits (PK1 , PK2, and PK3 ) 
Follow -up Visits 3-5 (PK1, PK 2, PK3 ) 
Component  Procedures  
Administrative and Regulatory  
 • Review/update  locator information  
• Visit questi onnaire  
• Provide reimbursement for study visit  
• Record/update AE s 
• Schedule next visit  as applicable   
Behavioral  • Adherence assessment  
• Provide modified counseling  
• Protocol adherence  
• Instructing participants to contact study staff when in labor/being 
admitt ed to labor and delivery   
• Study medication use/adherence  
Clinical  • Review/update med ical history  
• Review/update concomitant medications  
• Perform  modified  physical examination  
• Assess fetal heart tones  
• Provide available test results  (if applicable)  
• Administer timed dose of study medication  (PK1 and PK3 only)  
• Provide study medication with sufficient supply until next visit with 3 
additional doses  
• Participants will receive medication adherence log and/or be 
instructed on use of photo/video capture of daily dosing  
Laboratory  • Collect blood (plasma, DBS and PBMCs)  
• Intensive PK sampling (PK1, PK3) 
• Protein binding assay ( PK1, PK3) 
• Sparse PK plasma sampling (PK2) 
PRIOR TO VISIT DOSING , if applicable : 
• CBC  with differential and platelets  (PK1, PK2 ) 
• Hepatic function pane l (AST, ALT, albumin, total and direct 
bilirubin, alkaline phosphatase)  ( PK1, PK2 ) 
• PT/INR ( PK1, PK2 ) 
• Creatinine ( PK1, PK2 ) 
• Lipase ( PK1, PK2 ) 
• Creatin ine kinase ( PK1, PK2 ) 
• HCV RNA viral load   
• HCV Resistance Testing*  
*as indicated per protocol section 9.3  
 
Table 5a: 24 hour PK visit (PK1a and PK3a)  
Follow -up Visits 3a and 5a (PK1a and PK3a)  
Component  Procedures  
Administrative and Regulatory  
 • Visit questionnaire  
• Provide reimbursement for study visit  
• Record/update AE s 
Laboratory  • Collect blood  
• Sparse PK sa mpling  
 
 
 
VEL and SOF PK Evaluation  
 
For the PK1 and PK 3 visits (intensive PK), p articipants will be instructed not to take 
their daily dose at home but rather to bring their dose of SOF/ VEL to the visit for a 
timed administration.  Alternately, a dose w ill be dispensed by the PoR /designee  for 
 
 
SOF/VEL in Pregnancy, Version 5.0 33 December 2  , 2020  
 the PK visits.  Participants will be instructed about dietary restrictions for these visits 
as outline d in section 7.6.  Participants will have their first PK plasma draw n before 
the time of the dose of SOF/ VEL.  The dose at each PK visit will be timed and blood 
samples will be collected at each PK visit as follows (relative to the timed dose):  
pre-dose, 0.5, 1, 2, 3, 4, 5, 8 , and 12.  An intrav enous catheter may be placed  and 
used to obta ined samples  throughout the PK visits.  A saline solution will be used at 
a slow drip to attempt to keep the vein patent.  In the event that the catheter fails, 
participants may have another IV inserted or individual venipuncture (s) to attempt to 
collect a ll PK samples.  If still in place, t he catheter will be removed after the 12 hour 
time point. If a PK sample (s) cannot be obtained, then the participant will remain 
evaluable , if at  least one sample is obtained at each PK visi t.  Participants will return 
the following day for the 24 hour PK time point, which will be obtained by a single 
venipuncture.  The participant will be instructed to take their daily dose following the 
single blood sample collection .  For further details, see section 7.6 
Pharmacokineti cs.   
 
For the sparse PK visit (PK2), the time when the previous dose of SOF/VEL was 
taken will be recorded and a single PK sample will be collected.  This draw can 
occur at any time during the PK2 visit window and at any time during the day.   
 
7.4.2  End of Tre atment Visit (V6)  
The following procedures will occur at the End of Treatment visit.  This visit will be 
scheduled within 7 days of completion of the 12 week course of study medication.  
The purpose of this visit will be to collect any remaining study medi cation and to 
collect and follow up on any adverse events.  Participants will also be reminded to 
call th e research staff when they present to the hospital for delivery.  
 
Table 6 :  End of Treatment Visit  
End of Treatment Visit  
Component  Procedures  
Admin istrative and Regulatory  
 • Review/update locator information  
• Visit Questionnaire  
• In-depth Interview (IDI) ** 
• Provide reimbursement  
• Record/update AEs  
Behavioral  • Protocol adherence counseling , including delivery visit instructions  
• Collect remaining study med ication  
• Collect medication administration log  
Clinical  
 • Review/update medical history  
• Review/update concomitant medications  
• Perform modified physical examination  
• Provide available test results if available  
• Assess fetal heart tones (if applicable)  
Labora tory • HCV RNA viral load  
• HCV resistance testing*  
*as clinically indicated  
**May be performed at this visit or prior to post -treatment visit  (V7) 
 
 
 
SOF/VEL in Pregnancy, Version 5.0 34 December 2  , 2020  
 7.4.3  Delivery Visit  (in person visit or chart review)  
Participants  will be instructed to contact the study staff wh en they are in 
labor/admitted to labor and delivery, regardless of delivery location.  The Delivery 
Visit will occur during admission for participants  delivering at Magee -Womens 
Hospital and will include maternal and cord blood samples.  The date of the De livery 
Visit for participants  who deliver at Magee will be the date the study staff makes the 
first contact with the participant during her delivery admission, regardless if 
procedures occur over more than one day.  Participants  who deliver at an outside 
location will be contacted by phone as close to delivery as possible to complete the 
applicable Delivery Visit study procedures (i.e. questionnaire, update locator 
information, update medical history).  The Delivery Visit date for these participants  
will be  the date of the completed phone call.  All participants , regardless of delivery 
location will undergo a medical record review , if medical records are available  to 
obtain delivery outcomes/variables. A copy of the delivery records will be placed in 
the par ticipant’s research chart. In the event that the participant delivers prematurely  
at UPMC Magee -Womens Hospital  and is still taking study medication, then 
procedures from previously scheduled  visits (V2 -V6) may be performed, excl uding  
intensive PK sampling.  Rather than intensive PK sampling, a single maternal blood 
sample will be taken as close to the time of delivery as possible and cord blood wil l 
be collected for SOF/VEL  PK analysis.  
 
Table  7: Delivery Visit   
Delivery Visit  
Component  Procedures  
Administrative and Regulatory  
 • Review/update locator  information  
• Visit Questionnaire  
• Provide reimbursement , as applicable  
• Record/update AE s  
• Schedule next visit   
Behavioral  • Protocol adherence counseling  
• Study medication use/adherence (if still on study medication)  
Clinical  (Maternal) 
 • Review/update medical history  
• Review/update concomitant medications  
• Provide available test results  if available  
• Perform modified physical examination (or obtain from medical record)  
• Dispense study medication , as applicabl e to complete 12 week course 
(if still on study medication) * 
Clinical (Infant)  • Review medical history including pre -existing conditions  
• Review concomitant medications  
• Full physical examination (may be collected  via chart review)  
Medical Record Review  for 
Delivery Outcomes ^ • Type of pregnancy outcome  
• Gestational age at pregnancy outcome  
• Type of delivery (e.g., vaginal, vaginal forceps -assisted,  
vaginal vacuum -assisted, cesarean section)  
• Delivery medications  
• Complications related to pregnan cy outcome  
 Delivery complications (e.g., intrapartum and/or postpartum 
hemorrhage, non -reassuring fetal status, chorioamnionitis)  
 Other complications not related to a delivery  
 
 
SOF/VEL in Pregnancy, Version 5.0 35 December 2  , 2020  
 Baseline Infant Information ^** • Sex 
• Weight  
• Length  
• Head circumference  
• Apgar score s 
Laboratory *** • Maternal HCV  RNA  viral load  
• Cord blood collection for HCV RNA  viral load  
• Cord blood collection for PK analysis (if still on study medication)  
• Maternal plasma sample for PK analysis (if still on study medication)  
• HCV Resistance Testing  (if indicated)  
*Unless participant intends to breastfeed, in which case study medication will be discontinued . 
**All Baseline Infant Information may be extracted from the infant medical record as available . 
***Laboratory test s performed  as applicable for part icipants who deliver at Magee -Womens Hospital . 
^This information may be obtained by chart review abstraction and/or through extraction by R3.  
 
7.4.4  Post  Treatment  (V7) Visit  
The following procedures will occur at the Post  Treatment  visit (V7), which should be 
scheduled 12 weeks ± 4 days from the last dose of study medication .  The V7  visit 
can occur simultaneously with the 8 week  Follow -up Visit for the infant (iV1).   This is 
the last scheduled clinic visit for the maternal participant.  
 
Table  8: Post Treatment  (V7) 
Visit 7 (V7 ) Post  Treatment  Visit  
Component  Procedures  
Administrative and Regulatory  
 • Review/update locator  information  
• Visit questionnaire  
• Provide reimbursement  
• Record/update AE s  
Behavioral  • Protocol adherence counseling  
Clinical 
 • Review/update  medical history  
• Review/update concomitant medications  
• Perform modified physical examination   
• Provide available test results  from delivery , as applicable   
Laboratory  
 • Collect blood  
• CBC with platelets and differential  
• Hepatic function panel (AST, ALT, alb umin, total and direct 
bilirubin, alkaline phosphatase)  
• PT/INR  
• Creatinine  
• Lipase  
• Creatin ine kinase  
• HCV RNA  viral load  
• HCV resistance testing * 
*If HCV RNA is detectable, the participant would be asked to return to have HCV resistance testing done , and 
HCV resistance testing should be done  if the participant is still on study medication at time of delivery and study 
medication was discontinued at the delivery visit because the participant was planning to breastfeed . 
 
 
 
SOF/VEL in Pregnancy, Version 5.0 36 December 2  , 2020  
 7.4.5  Infant Follow -Up Visits (iV1, iV2 , iV3)  
After delivery, infants will be seen at the following time points:  
iV1:  8 weeks ± 6 weeks  
iV2:  6 months ± 2 weeks  
iV3:  12 months ± 2 weeks  
 
The following procedures will occur at the Infant Follow -Up Visits (iV1, iV2, iV3).  If 
blood sampling is  not possible, then  the results can be collected from the infant’ s 
medical record  if available .  Results of physical and developmental exams will be 
shared with the mother, and if necessary with the infant’s routine healthcare 
provider.  Referrals will be made as necessary.  
 
Table 9: Infant Follow -Up Visits (iV1, iV2, iV3)  
Visit iV1, iV2, iV3 Infant Follow -Up Visits  
Component  Procedures  
Administrative and Regulatory  
 • Review/update locator  information  
• Review infant demographics (iV1)  
• Sign release (s) for me dical records for infant  
• Provide reimbursement  
• Schedule next visit  (iV1, iV2)  
• Record/update AE’s  
• Document pre -existing conditions (iV1)  
Clinical 
 • Review/update medical history *** 
• Review/update concomitant medications *** 
• Growth assessment including weight,  length, and head 
circumference *** 
• Perform  age appropriate  physical examination   
• Developmental Exam ^ (iV2 and iV3 only) ; discuss results with mother , 
routine healthcare provider  if needed and provide referrals  (i.e. early 
intervention)  if necessary  
• Provi de available test results  as applicable (i.e. HCV RNA  test) 
Laboratory  
 • Collect infant blood  
• HCV RNA  (iV1, iV2 , and as applicable at iV3 )* 
• HCV resistance testing (if HCV RNA is detectable) ** 
^To include  an age appropriate d evelopmental exam, Bayley Scal es of Infant and Toddler Development,  and a 
general developmental screening tool completed by parents, Ages and Stages Questionnaire  (ASQ).  These 
evaluations will be done/reviewed by a qualified individual.  
*If HCV RNA is detectable  at iV1 or iV2 , the in fant would also have an HCV RNA performed at iV3 .  If HCV RNA 
is non -detectable/negative at both iV1 and iV2, no additional samples are needed.  If infant sample is unable to 
be collected at iV1 and/or iV2, a sample may be collected at iV3.  
**If HCV RNA i s detectable at iV1 or iV2, the infant would need to return to have HCV resistance testing . 
***May be collected from the medical record as applicable     
 
 
7.5 Follow -up Procedures for Participants Who Permanently Discontinue 
Study Medication  
 
Participants will be permanently discontinued for significant laboratory abnormalities 
or adverse events as outlined in section 9.3 and 9.4  or if they choose to discontinue 
the study medication . If participants  miss greater than one dose per week (averaged 
over the durati on of the study)  they may be discontinued at the discretion of the 
Protocol Chair/Principal Investigator.   Participants who are permanently discontinued 
from the study will be instructed to return the study medication  and study medication 
 
 
SOF/VEL in Pregnancy, Version 5.0 37 December 2  , 2020  
 log.  All prot ocol-specified study procedures may continue for safety except the 
following:  
• Provision of study medication  
• Provision of medication use adherence counseling  
 
The following procedures will be performed at the visit in which study medication use 
is perm anently discontinued:  
• Collection of blood for PK  analysis (single time point)  
• HCV resistance testing  
• Viral load as needed (i.e. participant withdraws, investigator opinion)  
• Medical history review  
• Concomitant medication review  
• Brief physical examination in cluding vital signs, if indicated.  
 
 
The participant will be asked to continue in the study and complete all remaining 
scheduled maternal and infant visits per protocol for safety.  
 
7.5.1  Interim Visits  
 
Interim visits may be performed at any time during the st udy. Study procedures may 
be repeated at interim visits as deemed clinically indicated.  All interim contacts and 
visits will be documented in participants' study records and on applicable CRFs.   
 
7.6 Pharmacokinetics  
 
All enrolled participants  will undergo intensive serum PK specimen collection 
procedures  at the PK1 and PK3 visits . These collections will occur at study visits as 
described in Table 9 .  
 
Table 9:  SOF and VEL PK Sampling  
Time since  
SOF/VEL*  Plasma  
Sample  Timed  
Meal  SOF/VEL 
PK sample 
(mL) Protei n 
Binding (mL)  PBMC /DBS  
sample (mL)  Total blood 
(mL) 
predose  +  4 0 4 8 
DOSING   +     
30 mins  +  4 0 0 4 
1 hour  +  4 0 0 4 
2 hours  +  4 6 0 10 
3 hours  +  4 0 0 4 
4 hours  +  4 0 0 4 
5 hours  +  4 0 0 4 
8 hours  +  4 0 0 4 
12 hours  +  4 0 0 4 
24 hou rs +  4 0 0 4 
 
 
SOF/VEL in Pregnancy, Version 5.0 38 December 2  , 2020  
 *Time listed is the target time for PK sample. If a sample is collected prior to next scheduled PK sample it will not 
be considered a protocol deviation.  Only missed samples will be considered protocol deviations.  
 
Participants will be inst ructed to bring their daily dose of SOF/VE L to the visits 
requiring intensive PK sampling (PK 1 and PK 3 visits) for timed administration .  If they 
do not bring their dose, then a dose of study medication can be dispensed from the  
pharmacy/PoR /designee .  Intravenous catheters may be placed during intensive PK 
visits.  A pre-dose sample will be collected .  Study drug will be administered as close 
as possible to the participant’s normal dose time if possible and within 5 minutes of 
completing a nd within 30 minutes of initiating a standardized moderate -fat-calorie 
breakfast (~600 calories and 25 to 30% fat) following an overnight fast (no food or 
liquids, except water, for at least 8 hours). Participants  will be restricted from food 
intake until after collection of the 4 hour blood draw and restricted from water 
consumption 1 hour before and 2 hours after dosing, except for approximately 240 mL 
of water given with study drug and standardized meal.  Whole blood will be collected 
into appropriate si zed Vacutainer® Plus plastic sterile tube(s) with K2EDTA (spray 
dried)  additive .  Immediately af ter collection, the collection tube will be inverted 8 to 
10 times to allow mixing with the anticoagulant  . Further processing instruction s can 
be found in the Specimen Collection and Procedures Manual.   
 
For the PK2 visit (sparse PK visit), a single 8mL blood sample (PK and PBMCs) will 
be drawn noting the time of the collection and the time at which the participant took 
their previous SOF/ VEL dose.  
 
7.7 Adherence Counseling and Assessment  
 
Adherence counseling to the study protocol will be performed at each study visit.   
Additionally, investigators may use text messaging (daily or weekly), follow -up phone 
calls, email,  and/or meeting study pa rticipants at their regular clinic visits in order to 
improve adherence to the study medication  and procedures .  All options will be 
included in the informed consent document and will be tailored to the participant’s 
needs.   At the follow -up visits (PK1, PK2, PK3 and End of Treatment Visit ), all 
remaining medication will be counted, recorded and returned to the pharmacy.  Study 
participants will be given a medication administration log  and also may be instructed 
on the use of photo/video capture of stud y medication administration using an IRB 
approved and secure mechanism   to assist in study medication adherence.  
Participants will take a photo/ video of themselves when taking their study medication 
daily through an IRB approved mechanism and send the photo/ video via text to the ID 
research designated study smart phone  or the photos/ videos may also be reviewed 
during study visits.  The provided paper log will have instructions on how and when to 
take the medication.  Research staff will reco mmend that participants take the study 
medication  consistently  at a time convenient for their schedule , preferably in the 
morning .  If a participant forgets to take a dose, she should take the missed dose as 
soon as she remembers but should not take more t han one tablet of SOF/VEL  per 
day.  Directions on how to store the medication as well as what to do if the medication 
is lost or stolen will be given to the participan t and included on the medication 
administration log  as applicable .  Participants will be asked to bring the medication 
 
 
SOF/VEL in Pregnancy, Version 5.0 39 December 2  , 2020  
 administration log  to the next study visit for review.  Medication administration logs  will 
be collected at the next visit and a new log  (as applicable)  will be given with each 
bottle/refill of study medication .  The completed  logs will be compared to the 
photos/ videos, as available.  Adherence counseling will be performed at the following 
visits: enrollment, PK1, PK2, and PK 3 (and at delivery if the participant has not 
completed the 12 weeks of study medication and is not brea stfeeding) .   
 
 
7.8 Clinical Evaluations and Procedures  
 
Physical exams will include the following assessments:  
 
• General appearance  
• Weight  
• Vital signs  
 Temperature  
 Pulse  
 Blood pressure  
 Respirations  
• Height ^ 
• Abdomen*  
• Head, Eye, Ear, Nose and Throat (HEENT) Ex amination*  
• Lymph nodes*  
• Neck*  
• Heart*  
• Lungs*  
• Extremities*  
• Skin*  
• Neurological*  
 
^obtained at Screening Visit only  
*may be omitted after the Enrollment Visit  
 
Additional clinical assessments may be performed at the discretion of the examining 
clinician in  response to symptoms or illnesses present at the time of the exam.  
 
 
7.9 Laboratory Evaluations  
 
Local Laboratory  (UPMC Clinical Laboratory)  
 
 
SOF/VEL in Pregnancy, Version 5.0 40 December 2  , 2020  
 • Blood  
o HIV serology   
o Hepatitis B Virus testing  
▪ HBsAg   
▪ Anti-HBc 
▪ Anti-HBs 
o PT/INR  
o Lipase  
o Creatine kinase  
o HCV  RNA  viral loa d: Maternal and Infant   
o Hepatitis C genotype  (as required at screening)  
o CBC with differential and platelets  
o Creatinine   
o Hepatic function panel  
▪ AST 
▪ ALT  
▪ Albumin  
▪ Total and direct bilirubin  
▪ Alkaline phosphatase  
 
Outside Laboratory  
• Blood  
o Blood PK  for SOF and VEL(University of Colorado ) 
o Dried Blood Spots and Peripheral Blood Mononuclear Cells for 
intracellular concentrations of the active SOF metabolite (GS -461230) 
(University of Colorado)  
o Protein Binding Assay ( University of Colorado ) 
o HCV Resistance Testing (Qu est Lab)  
 
7.10              In Depth Interviews  
 
 
At the screening visit and the end of treatment visit a trained interviewer from the Qual 
EASE team (CHRC Data Center, University of Pittsburgh) will conduct an in - depth 
interview about Hepatitis C infection, r isks of perinatal transmission, concerns about 
treatment during pregnancy and drug research during pregnancy.  The interviewer will 
use the HIP Script to conduct the interview.  All interviews will be recorded and 
transcribed verbatim.  The original record ings will be destroyed after transcription.  
The interview may be conducted at the visit or prior t o the nex t visit via phone or a 
secure video conferencing system.  
 
7.11 Specimen Collection and Processing  
 
The study site will adhere to the standards of good c linica l laboratory practice and 
standard operating procedures for proper collection, processing, labeling, transport, 
and storage of specimens. Specimens for SOF/VEL  PK analysis and protein binding 
 
 
SOF/VEL in Pregnancy, Version 5.0 41 December 2  , 2020  
 will be transported from the Clinical Research site to the  Magee -Womens Research 
Institute Microbiology Laboratory  for storage  until they are shipped to the appropriate 
laboratory for processing and analysis .  The samples will be shipped when arranged 
with the respective laboratories listed for PK analysis and pr otein binding . 
 
7.12 Biohazard Containment  
 
As the transmission of hepatitis C and other blood -borne pathogens can occur through 
contact with contaminated needles, blood, and blood medication s, appropriate blood 
and secretion precautions will be employed by all  personnel during blood draws and 
transport, shipping and handling of all specimens for this study as recommended by 
the CDC and National Institutes of Health (NIH). All biological specimens will be 
shipped using packaging mandated by Code of Federal Regul ations (CFR) 42 Part 
72. All dangerous goods materials, including diagnostic specimens and infectious 
substances, must be shipped according to instructions detailed in the International Air 
Transport Association (IATA) Dangerous Goods Regulations. Biohazar dous waste will 
be contained according to institutional, transportation/carrier, and all other applicable 
regulations.   
8 ASSESSMENT OF SAFETY  
 
8.1 Safety Monitoring  
 
Study investigators are responsible for continuous close safety monitoring of all stud y 
partic ipants, and for notifying  Gilead Sciences if unexpected and/or serious events 
occur . Two independent physician safety monitor s, who are not otherwise involved in 
the study  will review  the safety data once per month or more frequently as needed  
throughou t the period of study  implementation, discuss study medication 
management, and address any potential safety concerns.   
 
8.2 Clinical Data and Safety Review  
 
The clinical research investigators are  responsible for the initial evaluation and 
reporting of safety information at the participant level to the Protocol Chair.  The 
Protocol Chair is responsible for alerting Gilead Sciences  if unexpected concerns 
arise.  Additional reviews may be conducted at each of these levels as dictated by the 
occurrence of certain e vents.  
 
The Reproductive  Infectious Disease Data Management team will review incoming 
safety data on an ongoing basis.  Events identified as questionable, inconsistent, or 
unexplained will be queried for verification.  The clinical investigator  and two 
indep endent  safety  monitors (one obstetrician and one pediatrician)  will communicate 
approximately every month , as applicable  to review clinical data reports.  The content, 
format and frequency of the clinical data reports will be agreed upon by the 
independent safety monitor s and the study investigator s in advance of study 
implementation.  In addition to the routine safety data reviews, the independent safety 
 
 
SOF/VEL in Pregnancy, Version 5.0 42 December 2  , 2020  
 monitor s and the study investigators  will convene on an ad hoc basis to make 
decisions regarding the hand ling of any significant safety concerns.  If necessary, 
external experts represen ting expertise in the fields of pregnancy, newborn medicine, 
infectious diseases, hepatology and medical ethics may be invited to join the safety 
review.  A recommendation to pa use o r stop the trial may be made at this time or at 
any such time that the safety review team agrees that an unacceptable type and/or 
frequency of AEs has been observed.  
 
To assist in consistent and efficient concomitant medication recording for inpatient  
admissions (delivery and serious adverse event ), the UPMC Health Record Research 
Request ( R3) service may be used to  extract concomitant medications administered 
during any inpatient admission for maternal and infant study participants. If utilized, 
the extracted data will be provided to the study team in a format agreed upon by R3 
and data management.  Additional data may be extracted by R3 and/or the MOMI 
database to assist in data capture (i.e. APGARS, obstetric age, pregnancy outcomes).  
 
 
8.3 Adverse Even ts Definitions and Reporting Requirements  
 
8.3.1  Adverse Events  
 
An AE is defined as any untoward medical occurrence in a clinical research participant 
administered an investigational medication  and which does not necessarily have a 
causal relationship  with the  investigational medication . As such, an AE can be an 
unfavorable or unintended sign (including an abnormal laboratory finding, for 
example), symptom or disease temporally associated with the use of an 
investigational medication , whether or not considered related to the medication . The 
term “investigational medication ” for this study refers to the study medication.  
 
Study participants will be provided instructions for contacting the study site to report 
any untoward medical occurrences they may experience t hroughout their participation 
in the study.   Participants receiving prenatal care  and/or delivering  at Magee -Womens 
Hospital will be instructed to come to Magee -Womens Hospital if they experience any 
adverse events requiring evaluation. Participants will b e seen by a physician 
investigator/study clinician. If the participant is not receiving care at Magee -Womens 
Hospital, then they will be instructed to seek medical care with their local primary care 
physician /obstetrical team .  Participants may have an uns cheduled visit with the 
physician investigator/study clinicians as necessary or desired.  In cases of potentially 
life-threatening events, participants will be instructed to seek immediate emergency 
care. With appropriate permission of the participant, whe never possible, records from 
all non -study medical providers related to untoward medical occurrences will be 
obtained and required data elements will be abstracted and recorded on study CRFs. 
All participants reporting an untoward medical occurrence will b e followed clinically as 
deemed appropriate by a physician investigator until the occurrence resolves (returns 
to baseline) or stabilizes.  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 43 December 2  , 2020  
 Study site staff will document AEs reported by or observed in enrolled study 
participants by severity and presumed r elationship to investigational medication , 
including gradable laboratory findings. Medication from hospital admissions may be 
extracted from the medical record using the UPMC Health Record Research Request 
(R3) service and/or MOMI database to ensure consis tency and accuracy of reporting.  
 
Some of the study participants will have opioid use disorder (OUD) and may be 
prescribed either methadone or buprenorphine as treatment. Infants who are exposed 
to these medications often experience neonatal opioid withdr awal syndrome (NOWS). 
Given that this is an expected outcome for this treatment, we will not report this as an 
AE. All opioid exposed infants in the UPMC hospital system have at minimum a 5 -day 
observation period and those who require pharmacologic treatme nt for NOWS can 
remain in the hospital for up to a month (mean 14 days). A study pediatrician , will 
review all NOWS related hospitalization records to ensure that there are no hospital 
events that are outside the scope of standard NOWS fi ndings, for example 
pneumonia, sepsis, and hypoglycemia.  
 
Additionally, certain adverse events are expected as a consequence of labor and 
delivery.  Prior to delivery, expected pregnancy findings, such as lower extremity 
edema, physiologic discharge of pre gnancy, and pain from contractions as determined 
by a study clinician will not be considered adverse events. During the postpartum 
period, expected pregnancy findings such as lower extremity edema, abdominal pain 
from uterine cramping, incisional pain from  a cesarean section, perineal pain after 
vaginal delivery, and vaginal bleeding as determined by a study clinician will not be 
considered  adverse events. Expected  symptoms  may be further defined and reported 
accordingly in a protocol specific standar d operating procedure (SOP) or guidance 
document.   
 
AE severity will be graded per the most current DAIDS Table for Grading Adult and 
Pediatric Adverse Events .   
 
8.3.2  Serious Adverse Events  
 
An SAE wil l be defined as  an AE that:  
 
• Results in death  
• Is life -threatening  
• Requires inpatient hospitalization or prolongation of existing hospitalization, 
except those that are expected such as hospitalization for neonatal opioid 
withdrawal syndrome.  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
• Is an important medical event that may not result in death, be immediately life -
threatening, or require hospitalization but may jeopardize the participant or 
require intervention to prevent one of the outcomes listed in the definition 
above.  
 
 
SOF/VEL in Pregnancy, Version 5.0 44 December 2  , 2020  
  
8.3.3  Adverse Event Relationship to Study Medication  
 
Related ness is an assessment made by the physician investigator of whether or not 
the event is related to the study agent.   
• Related:  There is a reasonable possibility that the AE may be related to the 
study agent(s)  
• Not Related:  There is not a reasonable possibility that the AE is related to the 
study agent(s)  
 
8.4 Expedited Adverse Event Reporting Requirements  
 
8.4.1  Reporting Requirement s for this Study  
 
All adverse events will be reported to Gilead Sciences on a monthly basis.   All serious 
adverse events that are considered unexpected and related to the study medication 
will be reported to the University of Pittsburgh Institutional Revie w Board, the FDA and 
Gilead Sciences according to the ir reporting guidelines .   
 
8.4.2    Grading Severity of Events  
 
The most current Division of AIDS Table for Grading the Severity of Adult and Pediatric 
Adverse Events (DAIDS AE Grading Table)  is available on t he RSC website at 
http://rsc.tech -res.com/safetyandpharmacovigilance/ . 
 
 
8.5 Regulatory Requirements  
 
Information on all applicable AEs will be included in reports to the FDA and other 
applica ble government and regulatory authorities.  The Protocol Chair will submit AE 
information in accorda nce with the requirements  of the University of Pittsburgh IRB . 
 
8.6 Social Harms Reporting  
 
Although every effort will be made to protect participant privacy and  confidentiality, it 
is possible that participants’ involvement in the study could become known to others 
and that social harms may result.  Social harms that are judged by the study 
investigators to be serious or une xpected will be reported to Gilead Scien ces and to 
the University of Pittsburgh IRB.   
 
 
 
 
SOF/VEL in Pregnancy, Version 5.0 45 December 2  , 2020  
 9 CLINICAL MANAGEMENT  
 
Guidelines for clinical management and permanent discontinuation of study 
medication  are outlined in this section.  In general, the physician  investigators will only 
discontinue study medication  in consultation with the independent physician safety 
monitor (s) if they feel that the risk of study medication  continuation outweighs the 
benefits of study medication  continuation . The physician investigator (s) will document 
all permanent disconti nuations on applicable CRFs.  
 
9.1 Grading System  
 
AE severity grading is described in Section 8.3.1.  
 
9.2 Dose Modification Instructions  
 
No dose modifications will be permitted  in this study.  
 
9.3 General Criteria for Permanent Discontinuation of Study Medication  
 
A participant will be permanently discontinued from medication  use by the physician  
investigator (s) for any of the following reasons , according the HCV treatment 
guidelines23:  
 
• 5-fold or greater increase in ALT or AST at the PK1 or PK2 visit compared to 
baseline result ( Screening visit ), confirmed by immediate repeat testing  
• Any increase of ALT or AST of less than 5-fold from baseline (Screening visit) 
at the PK1 or PK2 visit that is accompanied by any weakness, nausea, 
vomiting, or jaundice  
• 3-fold or greate r increase in ALT or AST accompanied by bilirubin >2x the 
upper limit of normal, confirmed on immediate repeat testing  
• Increase HCV RNA viral load by greater than 10 -fold at PK2 visit ( 6-8 weeks 
after starting treatment ) 
• Participant is unable or unwilling to comply with required study procedures  
• If the participant delivers prematurely (and is still on study medication) and 
desires to breastfeed  
• Participant might be put at undue risk to their safety and well -being by 
continuing medication use, according to the judgment of the study 
investigator (s). The study investigators will consult with the independent safety 
physician  prior to all study medication  discontinuation instituted for this reason.   
 
Any time a participant is permanently discontinued from study medication (prior to 
completion of the 12 week course of study medication), HCV resistance testing will be 
performed.  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 46 December 2  , 2020  
 9.4 Permanent Discontinuation in Response to Adverse Events  
 
Grade 1 or 2  
In general, a participant who develops a Grade 1 or 2 AE  as define d by the DAIDS 
Table for Grading Adult and Pediatric Adverse Events, Version 1.0 , December 2004 
(Clarification dated August 2009) regardless of relationship  to study medication  will 
continue study medication  use.  
 
Grade 3  
For participants who develop a Gr ade 3 AE as defined by the DAIDS Table for Grading 
Adult and Pediatric Adverse Events, Version 1.0 , December 2004 (Clarification dated 
August 2009) that is judged by the study investigators  to be unrelated to study 
medication , the study medication  will con tinue.   The study medication  must be 
permanently discontinued for  participants who de velop a Grade 3 AE judged by a 
physician  investigator to be related  to the study medication . 
 
Grade 4  
If a participant  develop s a Grade 4 AE as defined by the DAIDS Table for Grading 
Adult and Pediatric Adverse Events, Version 1.0 , December 2004 (C larification dated 
August 2009)  and the AE is determined to be  related to study medication, then study 
medication  must be permanently discontinued.  
 
Any time a participant is perm anently discontinued from study medication (prior to 
completion of the 12 week course of study medication), HCV resistance testing will be 
performed.  
 
9.5 HIV-1 Infection  
 
Participants who are positive for HIV (known or positive at Screening) will not be 
eligible to participate.  If HIV seroconversion occurs during the time of study 
medication use, the study medication will continue.     
 
9.6 Criteria for Early Termination of Study Participation  
 
Participants may voluntarily withdraw from the study for any reason at any time.  The 
study investigators  also may withdraw participants from the study to protect their 
safety and/or if they are unwilling or unable to comply with required study procedures . 
Participants also may be withdrawn if Gilead  Sciences , government or  regulatory 
authorities, including the FDA and Office for Human Research Protections (OHRP), 
or site IRBs/ECs terminate the study prior to its planned end date.  Detailed reason for 
the withdrawal of a participant will be document ed in the research record.  Every 
reasonable effort will be  made to continue to follow the participant as scheduled for 
safety .     
 
 
SOF/VEL in Pregnancy, Version 5.0 47 December 2  , 2020  
 10 STATISTICAL CONSIDERATIONS  
 
10.1 Overview and Summary of Design  
This is a Phase 1, single -arm, open label study of treatment  for chronic HCV 
infection durin g pregnancy in 10 HCV -infected pregnant women with a 12 -week 
course of SOF/VEL . 
 
10.2 Study Endpoints  
 
Pregnant women meeting all of the criteria in section 5.2 and 5.3 will be enrolled into 
the study and  followed prospectively through 12 weeks after the last d ose of study 
medication .  Infants will be enrolled upon delivery and followed prospectively through 
approximately one year of age.  
10.2.1  Primary Endpoints : Maternal  
The primary endpoints of the study are primary plasma PK parameters (specifically 
AUC tau, Cmax, and C min) of VEL, SOF, and GS -331007 assessed  at 3 weeks (+/ - 7 
days of medication initiation.    
 
10.2.2            Secondary Endpoints : Maternal  
 
The secondary endpoints of the study are:  
1) Secondary plasma PK endpoints of VEL, SOF and GS -331007:  
a. Free-fraction of VEL, SOF and GS -331007  
2) Secondary PK endpoints for intracellular SOF ( GS-461203)  
a. Pre-dose GS-461203 concentrations  from dried blood spots and 
peripheral blood mononuclear cells  
3) Maternal sustained virologic response after 12 weeks of therapy ( SVR12) 
4) Adverse events including clinical  and laboratory changes  
5) Pregnancy outcomes including the following:  
a. delivery prior to 37 completed weeks of gestation  
b. stillbirth or intrauterine fetal demise  
c. intrapartum hemorrhage  
d. postpartum hemorrhage  
e. non-reassuring feta l status  
f. chorioamnionitis  
g. hypertensive disorders of pregnancy  
h. gestational diabetes  
i. intrauterine growth restriction  
10.2.3  Exploratory  Endpoints  
 
The exploratory endpoint of the study is:  
 
 
SOF/VEL in Pregnancy, Version 5.0 48 December 2  , 2020  
 1.) In depth interviews conducted before enrollment in screened participants and  
after completion of treatment in enrolled participants.  
 
Secondary Endpoints: Infant   
Consistent with the secondary study objectives, the following secondary endpoint 
will be assessed for infants:  
 Major malformations, defined as structural abnormalities w ith surgical, 
medical, or cosmetic importance.  
 Weight, length, and head circumference at birth, 8 weeks , six months and 12 
months.  
 Neurodevelopmental assessments at 6 months and 12 months as measured 
by Bayley Scales of Infant and Toddler Development and A ges and Stages 
Questionnaire  (ASQ) . 
 Perinatal HCV transmission assessed by presence of HCV RNA at 8 weeks , 
six months  or 12 months . 
 
10.3 Sample Size  
To evaluate the primary objective, we estimate a desired sample size of 10 
participants.  In order to maintain our sample size, any participant who discontinues 
treatment during the 12 -week treatment period will be replaced.  Based on SOF/VEL 
prescribing information, we will have 87% power to detect a 50% decrease in VEL 
AUC and >99% power to detect a 2 -fold increa se. For power calculations we chose 
this degree of change in VEL AUC because the therapeutic range of SOF/VEL is 
quite wide and decreases in VEL AUC of up to 50% and increases of up to 2 -fold are 
still associated with efficacy and have acceptable safety/to lerability, respectively. 
The FDA does not recommend co -administration of VEL with EFV because it 
decreases the VEL AUC by >50% [34].  Additionally, this sample size provides an 
estimated power of 0.82 to detect a 25% change in the AUC of the SOF, given th e 
reported interpatient variability of 35.6% among female patients Power 
determinations were performed in SAS v. 9.4 (SAS, Cary, NC).  
 
Any participant that discontinues the study before the PK3 visit is completed  or if a 
participant reports missing more th an 1 dose per week averaged over the duration of 
the study then they  will be replaced by recruiting another participant into the study.   
 
10.4 Participant Accrual and Retention  
 
Pregnant and chronically HCV -infected women who meet the criteria outlined in 
Section 5 and are interested in participating, will be enrolled into this study. Once a 
participant is enrolled, the study staff will make every reasonable effort to retain her 
for the entire study period.  Any participant lost to follow -up prior to Visit 7 wil l be 
replaced.  
  
 
 
SOF/VEL in Pregnancy, Version 5.0 49 December 2  , 2020  
 10.5 Data Analysis  
10.5.1 Analysis of SOF and VEL concentrations  
Between -group comparisons will evaluate changes in SOF and VEL PK parameters 
between the historical controls (nonpregnant women  without severe renal disease or 
cirrhosis ) compare d to the 10 pregnant women. Area under the time concentration 
cure over a dosing interval (AUC tau), maximum concentration (C max), and minimum 
concentration ( Cmin) will be calculated , as applicable .  The PK parameters  (including 
the free -fraction  of VEL  and intracellular SOF concentrations)  of the pregnant 
women  will be compared to the historical control group  by calculating the geometric 
mean ratios and 90%CIs . Drug concentrations will be summarized descriptively 
(mean, median, minimum, maximum, standard de viation) by study visit .    
 
10.5.2  Analysis of SVR12  
 
Outside of pregnancy, 9 9% of patients treated with SOF/VEL  for 12 weeks obtained 
an SVR12 .  In this pilot study, we estimate that at least 9 out of the 10 chronically 
HCV -infected pregnant women will h ave a SVR12  after treatment.  Participants who 
do not complete the treatment course or report low adherence will be excluded from 
the analysis.  
 
10.5.3 Analysis of Safety Endpoints  
 
Rates of abnormal safety laboratory assessments will be compared to those 
reported in the literature on historic controls and rates of adverse pregnancy 
outcomes will be compared to historic HCV -infected pregnant women who have 
delivered at our institution.  Statistical significance will be determined by chi -square 
test. 
 
Qualit ative Analysis  
 
Following transcription of the IDIs, the Qual EASE team will develop a qualitative 
codebook using an editing approach to ensure that all relevant topics and themes 
are represented. Two trained qualitative coders from Qual EASE will then be trained 
in the codebook. A primary coder will code all interviews in the pre - and post - 
treatment interview groups, and a secondary coder will code half of the  interviews in 
the pre - and post -treatment interview groups. Coding will be completed using Atlas .ti 
software, which will help to determine the frequency and prevalence of the topics 
and themes which were discussed. Cohen’s Kappa scores will be calculated to 
determine intercoder reliability.   
 
 
10.5.4 Data and Safety Monitoring Plan  
 
No Data and Safety Monitoring Board oversight is planned for this study , however a 
Study Steering Committee comprised by the Protocol Chair, a second physician 
 
 
SOF/VEL in Pregnancy, Version 5.0 50 December 2  , 2020  
 investigator from the University of Pittsburgh, a laboratory scientist from the 
University of Pittsburgh, the Data Management lead statistician and a representative 
from Gilead Sciences Clinical Research will provide oversight . Reviews of study 
progress, including rates of participant accrual, retention, completion of primary and 
main secondary endpoint assessments will take place approximately every 3 
months, and as needed.  At the time of these reviews, or at any other time, the 
Study Steering Committee may recommend that the study proceed as designed, 
proceed with design modifications, or be discontinued.  Two independent safety 
physician s experienced with monitoring of clinical trials among pregnant women will 
conduct interim safety reviews on a monthly basis or more freq uently at the request 
of the Study Steering Committee.  
11 DATA HANDLING AND RECORDKEEPING  
 
11.1 Data Management Responsibilities  
 
Study questionnaires will be developed by the study team in conjunction with data 
management .  
 
11.2 Source Documents and Access to Source  Data/Documents  
 
The site will maintain source data/documents in accordance with current DAIDS 
policies. ( http://rsc.tech -res.com/policiesandregulations/ )  
 
The study team will maintain, and s tore securely, complete, accurate and current 
study records throughout the study.  In accordance with U.S. regulations regarding 
testing investigational medication s, the study investigator will maintain all study 
documentation for at least two years followi ng the date of marketing approval for the 
study medication s being tested for the indication in which they were studied.  If no 
marketing application is filed, or if the application is not approved, the records will be 
retained for two years after the invest igation is discontinued and the US FDA is 
notified.  For research involving children, records shall be retained at least until the 
pediatric subject reaches the age of 23.  
 
Study records will be maintained on site for the entire period of study implementati on.  
 
11.3 Quality Control and Quality Assurance  
 
The study site will conduct quality control and quality assurance procedures in 
accorda nce with site SOPs.   
 
 
SOF/VEL in Pregnancy, Version 5.0 51 December 2  , 2020  
 12 CLINICAL SITE MONITORING  
 
As this is an investigator initiated IND study, monitoring will be performed by internal 
clinical study staff (i.e. QA/QC Reviewer), PoR, laboratory staff and local data 
management team.   Internal reviews will include:  
 
• Review informed consent forms, protocol procedures, and study 
documentation  
• Assess compliance with the study pro tocol, Good Clinical Practices (GCP) 
guidelines, and applicable regulatory requirements (US and non -US), 
including CFR Title 45 Part 46 and Title 21 Parts 50, 56, and 312  
• Perform source document verification to ensure the accuracy and 
completeness of stud y data  
• Verify proper collection and storage of biological specimens  
• Verify proper storage, dispensing, and accountability of investigational study 
medication s 
 
The Education and Compliance Support for Human Subject Research (ECS -HSR),  
Office of Research Protections will also oversee study activities.   The ECS -HSR has 
extensive experience in the auditing and monitoring of clinical investigations for 
compliance with GCP standards and IND commitments. To ensure appropriate 
institutional oversight of University -based IND applications, the ECS -HSR will 
periodically monitor the research oversight programs of IND Sponsors, which will 
include compliance of the Sponsor and Investigator with applicable FDA regulations,  
applicable University of Pittsburgh policies and the IRB -approved protocol and 
consent document. The frequency of these monitoring visits shall be  
determined by the ECS -HSR.  
The study investigators also will allow inspection of all study -related documentation 
by authorized represen tatives of Gilead  Sciences , FDA, OHRP, IRBs/ECs and other 
local and US regulatory authorities.   
13 HUMAN SUBJECTS PROTECTIONS  
 
Study investigators will make efforts to minimize risks to participants. Informed 
consent will be reviewed in detail with potential participants and all questions will be 
adequately answered prior to obtaining written informed consent.  All eligibility 
criteria will be verified prior to initiation of investigational product.  Recruitment will 
begin after receiving IRB approval and afte r the protocol has been submitted to the 
FDA.  The study investigators will permit audits by the NIH, Gilead Sciences, the 
FDA, OHRP, IRB, and other local and US regulatory authorities or any of their 
appointed agents.  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 52 December 2  , 2020  
 13.1 Institutional Review Boards  
 
The stu dy staff will ensure that the protocol, associated informed consent form, and 
study -related documents (such as participant education and recruitment materials) 
are reviewed and approved by the University of Pittsburgh IRB prior to starting the 
study. Any a mendments to the protocol or informed consent will be approved by the 
University of Pittsburgh IRB prior to implementation.  
 
13.2 Study Coordination  
 
Catherine Chappell, MD MSc holds the Investigati onal New Drug (IND) application  for 
this study . Assignment of a ll sponsor responsibilities for this study will be specified in 
a Clinical Trials Agreement (CTA) execu ted by the University of Pittsburgh and Gilead  
Sciences .  Dr. Chappell will work closely with The University of Pittsburgh Office  for 
Investigator -Sponso red IND and IDE Support (O3IS) who provides assistance to 
University researchers in order to ensure IND submission and notification 
requirements are met.   
 
Close coordination between the study team is necessary to track recruitment, 
enrollment, retention,  AEs and unanticipated problems and to address other issues 
that may  arise in a timely manner. The study investigators and the independent safety 
physician will address issues related to study eligibility,  AE management/reporting and 
unanticipated problems  as needed to assure consistency. Rates of accrual, protocol 
adherence, retention, and AE incidence will be reported by data management an d 
monitored closely by the team as well as the Study Steering Committee . 
 
13.3 Risk Benefit Statement  
 
13.3.1  Risks  
 
General /Mater nal 
 
As with any research study, there may be adverse events or side effects for the 
maternal participant or the fetus/infant that are currently unknown and certain of these 
unknown risks could be permanent, severe or life -threatening.  
 
There are no studie s of SOF/VEL  in pregnant women.  However there has been one 
study of a similar medication ledipasvir/sofosbuvir in 9 pregnant women.  There were 
no adverse events greater that grade 2 that were related ledipasvir/sofosbuvir.  There 
have been animal studies  done in rats and rabbits as detailed in section 2.4.2.  No 
effects on fetal development have been observed in rats and rabbits at the highest 
doses tested.  However, animal reproductive studies are not always predictive of 
human response.  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 53 December 2  , 2020  
 It is also not  known if SOF/VEL  is present in human breast milk.  If the participant 
delivers while still on study medication and intends to breast feed, study medication 
will be discontinued and HCV resistance testing will be done  at the next study visit .  
 
There is a potential risk that the hepatitis virus may become resistant to SOF/VEL  
because the dose may not be adequate for treating pregnant women with hepatitis C 
or if the participant does not complete the entire 12 weeks of study medication.  If 
resistance occurs , this may limit the choices of effective therapy after pregnancy for 
the participant and/or possibly her infant.  
 
Overall, SOF/VEL was well tolerated by patients with chronic HCV infection (N=1035) 
with only 2 participants permanently discontinued treatm ent due to adverse events 
(0.2% ).  The most common adverse reactions (adverse events assessed as causally 
related by the investigator and at least 10%) were headache and fatigue.  Adverse 
reactions, all grades, observed in greater than or equal to 5% o f participants receiving 
12 weeks of treatment with SOF/VEL in ASTRAL -1 include : headache (22%), fatigue 
(15%), nausea (9%), asthenia (5%), and insomnia (5%). Of subjects receiving 
SOF/VEL , 79% had an adverse reaction of mild severity (Grade 1). With the e xception 
of asthenia, each of these adverse reactions occurred at a similar frequency or more 
frequently in participants treated with placebo compared to participants treated with 
SOF/VEL (asthenia: 3% versus 5% for the placebo and SOF/VEL groups, 
respecti vely).  The adverse reactions observed in participants treated with SOF/VEL 
in ASTRAL -2 and ASTRAL -3 were consistent with those observed in ASTRAL -1. 
Irritability was also observed in greater than or equal to 5% of participants treated with 
SOF/VEL in ASTR AL-3.  In the ASTRAL -1 study, rash occurred in 2% of participants 
treated with SOF/VEL and in 1% of participants taking placebo. No serious adverse 
reactions of rash occur ed and all rashes were mild or moderate in severity.  In the 
ASTRAL -1 study, depress ed mood occurred in 1% of participants treated with 
SOF/VEL and was not reported by any placebo participants. No serious adverse 
reactions of depressed mood occur ed and all events were mild or moderate in 
severity.   
 
Hepatitis B virus (HBV) reactivation has been reported in HCV/HBV coinfected 
patients who were undergoing or had completed treatment with HCV direct acting 
antivirals, and who were not receiving HBV antiviral therapy. Some cases have 
resulted in fulminant hepatitis, hepatic failure, and death . Cases have been reported 
in patients who are HBsAg positive and also in patients with serologic evidence of 
resolved HBV infection (i.e., HBsAg negative and anti -HBc positive).  We will 
exclude participants that are anti -HBc positive for this reason.   A dditionally, 
postmarketing cases of symptomatic bradycardia and cases requiring pacemaker 
intervention have been reported when amiodarone is coadministered with a 
sofosbuvir -containing regimen. Additionally , a fatal cardiac arrest occurred in a 
patient ta king amiodarone that was co -administered with sofosbuvir.  For this 
reason , we will exclude participants who are taking amiodarone.   
 
 
SOF/VEL in Pregnancy, Version 5.0 54 December 2  , 2020  
  
Laboratory abnormalities:  
Lipase Elevations: In ASTRAL -1, isolated, asymptomatic lipase elevations of greater 
than 3 tim es the upper limit of normal were observed in 3% and 1% of participants 
treated with SOF/VEL and placebo for 12 weeks, respectively; and in 6% and 3% of 
participants treated with SOF/VEL in ASTRAL -2 and ASTRAL -3, respectively.  
Creatine Kinase: In ASTRAL -1, isolated, asymptomatic creatine kinase elevations 
greater than or equal to 10 times the upper limit of normal were reported in 1% and 
0% of participants treated with SOF/VEL and placebo for 12 weeks, respectively; 
and in 2% and 1% of participants treated  with SOF/VEL in ASTRAL -2 and ASTRAL -
3, respectively.  
 
There are known drug interactions with SOF/VEL  and other prescription and non -
prescription medications.  A comprehensive list of medications will be obtained from 
participants including over -the-counte r medications (i.e. antacids, St. John’s wort) and 
compared to the package insert to assess any contraindication to participation or 
necessary alterations in dosing schedules with use of the study medication.   
 
Phlebotomy or starting an IV may lead to exc essive bleeding, discomfort, feelings of 
dizziness or faintness, and/or bruising, swelling and/or infection.   
 
Disclosure of HIV status may cause worry, sadness or depression.  Disclosure of HIV -
positive status has been associated with depression, suicidal ideation, and denial as 
well as social isolation.  Trained counselors will be available to help participants deal 
with these feelings.   
 
Participation in clinical  research includes the risk  of confidentiality loss . 
 
Participants will be asked to provide pe rsonal/protected health information (PHI).  All 
attempts will be made to keep PHI confidential within the limits of the law.  However, 
there is a chance that unauthorized persons will see PHI.  All paper records will be 
kept in a locked file cabinet or mai ntained in a locked room at Magee.  Electronic files 
will be password protected.  Only people who are involved in the conduct, oversight, 
monitoring, or auditing of this study will be allowed access to the PHI that is collected.  
Any publications from this  study will not use information that will identify participants 
by name.  Organizations that may inspect and/or copy research records maintained 
at the participating sites for quality assurance and data analysis include groups such 
as the study sponsor, the National Institute of Health (NIH) or its designee and the US 
Food and Drug Administration (FDA).  
 
Technology assisted -directly observed therapy : There  is a risk that people outside of 
the research team will see the directly observed dosing. The photo/ video recording 
 
 
SOF/VEL in Pregnancy, Version 5.0 55 December 2  , 2020  
 of the dosing will be taken directly into the PittBox app and stored in this system for 
the research staff to access.  .  While the app is password protected, someone may 
access the information if they gain access to the password/app on the participant ’s 
personal device.  Likewise, the telephone numbers for these communications could 
also be visible to third parties.   
 
Fetus/infan t:   
There is not data on use of this medication during pregnancy so the effects on a 
fetus/unborn child are not known.  The study medication may cross the placenta and 
get to the fetus/unborn infant exposing the fetus to the study medication.  It is unkno wn 
whether a fetus/unborn infant whose mother took SOF/VEL  during pregnancy will 
develop normally or have side effects.   
 
Obtaining blood samples from the infant may cause them to cry, cause bleeding, 
bruising or a clot and may be distressful to watch the  infant have their blood drawn.   
 
13.3.2  Benefits  
 
This study is a safety study of use of SOF/VEL  in pregnancy and as such the study 
medication may not treat HCV in pregnancy as it may not be the correct dose. 
Participants and others may benefit in the future fr om information learned from this 
study.  Specifically, information learned in this study may lead  evidence -based 
guidance for the treatment of chronic hepatitis C infection in pregnancy  and prevention 
of perinatal HCV transmission .  
 
 
13.4 Informed Consent Proc ess 
 
Written informed consent will be obtained from each study participant prior to 
performing study procedures. Consent may be obtained electronically if approved by 
the IRB and utilizing an IRB approved mechanism.  In obtaining and documenting 
informed c onsent, the study investigators will comply with applicable local and US 
regulatory requirements and will adhere to GCP and to the ethical principles that have 
their origin in the Declaration of Helsinki. Participants may be provided with a copy of 
the inf ormed consent form if they chose.  
 
The informed consent process will cover all elements of informed consent required by 
research regulations.  In addition, the process specifically will address the following 
topics of importance to this study:  
 
• The unknown safety and proven efficacy of the study medication s 
• The importance of daily adherence to the study medication  
• The importance of adherence to the study visit and procedures schedule  
• The potential medical risks of study participation (and what to do if such  risks 
are experienced)  
 
 
SOF/VEL in Pregnancy, Version 5.0 56 December 2  , 2020  
 • The benefits of study participation  
• The distinction between research and clinical care  
• The right to withdraw from the stu dy at any time  
 
13.5 Participant Confidentiality  
 
All study procedures will be conducted in private, and every effort will be made to 
protect participant privacy and confidentiality to the extent possible.  All study -related 
information will be stored securely a t the clinical research unit . All participant 
information will be stored in locked areas with access limited to the clinical study staff.  
All laboratory specimens, study data collection, and administrative forms will be 
identified by coded number  (PTID)  only to maintain participant confidentiality.  All 
records that contain names or other personal identifiers, such as locator forms and 
informed consent forms, will be stored electronically in the  University of Pittsburgh  
REDCap system. Appropriate firewall an d virus scanning software are installed and 
updated routinely by hospital support staff. Forms, lists, logbooks, appointment books, 
and any other listings that link participants’ ID numbers  (PTID)  to identifying 
information will be stored in a separate, lo cked area with limited access.  Participants’ 
study information will not be released without their written permission, except as 
necessary for review, monitoring, and/or auditing by the following:  
 
• Representatives of the US Federal Government, includ ing the  US FDA, the 
US OHRP  and other local and US regulatory authorities  
• Representatives of  Gilead Sciences  
• Study staff  
• University of Pittsburgh IRB  
• University of Pittsburgh Education  and Compliance Office for Human Subject 
Research (ECO -HSR)  
 
13.6 Special Populatio ns 
 
13.6.1  Pregnant Women  
 
Pregnant women will be offered enrollment in this study in accordance with guidelines  
set forth in the US 45 CFR 46.  
 
13.6.2  Children  
 
Infant procedures will begin  at the time of delivery  if delivered at Magee -Womens 
Hospital or at iV1 visit i f infant delivered outside of Magee -Womens Hospital in 
accordance with guidelines set forth in the US 45 CFR 46 and DAIDS policy  
(http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Document
s/enrollingchildrenrequirements.pdf).  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 57 December 2  , 2020  
 13.7 Compensatio n 
 
 Participants will be compensated for time and effort in this study, and/or be 
reimbursed for travel to study visits and time away from work. Reimbursement 
amounts will be specified in the informed consent form.  Compensation may i nclude 
parking/bus passes , assistance with transportation,  and additional incentives for 
making study appointments within the window period.   If needed and desired, 
compensation for overnight stay during the PK -1 and PK-3 visits may be provided to 
particip ants.  
 
13.8 Communicable Disease Reporting  
 
Study staff will comply with local requirements to report communicable diseases 
including HIV -1 identified among study participants to health authorities.  Participants 
will be made aware of reporting requirements dur ing the informed consent process.  
 
13.9 Access to HIV -related Care  
 
13.9.1  HIV Counseling and Testing  
 
HIV testing will be performed at Screening. HIV test -related counseling will be 
provided to all potential study participants who consent to undergo HIV -1 screening t o 
determine eligibility for participation.  Counseling will be provided in accordance with 
standard HIV counseling policies and methods.   Participants are expected to have 
HIV screening as part of routine prenatal care at 28 weeks’ gestation , and  if clinic ally 
indicated during the study . 
 
13.9.2  Care for Participants Identified as HIV -Positive  
 
Identified as HIV -Positive Prior to Enrollment  
An individual who has been identified as infected with HIV -1 will not be eligible to 
participate and will be referred  to the Pittsburgh AIDS Center for Treatment (PACT) .  
 
Identified as HIV -Positive While on Study Medication  
The participant will continue with the study medication and study procedures, and will 
be immediately referred to PACT  or another clinic/provider convenien t for the patient .   
 
13.10  Study Discontinuation  
 
This study may be discontinued  at any time by Gilead  Sciences , the US FDA, the 
OHRP, other government or regulato ry authorities, or the University of Pittsburgh IRB . 
 
 
SOF/VEL in Pregnancy, Version 5.0 58 December 2  , 2020  
 14 PUBLICATION POLICY  
The University of Pittsburg h study investigators will be responsible for publication of 
the results of this study. The manuscript draft will be sent to Gilead Sciences 
approximately 30 days prior to submission for  their review and  approval.   
 
15 APPENDICES  
 
 
 
SOF/VEL in Pregnancy, Version 5.0 59 December 2  , 2020  
 APPENDIX I: SCHEDULE OF ST UDY VISITS AND EVALUATIONS  (Mother)  
    SCR  
(V1) ENR  
(V2) PK1, PK2, PK3  
(V3, V4, V5)   
PK1a, PK2a  
(V3a, V5a)  End of 
Treatment 
(V6) Delivery**  Post treatment  
(V7) 
ADMINISTRATIVE AND REGULATORY              
Informed consent  X           
Assess informed cons ent comprehension  X           
Assignment of PTID  X           
Locator information  X X X  X X X 
Demographic information  X           
Visit Questionnaire  X X X X X X X 
In-depth Interview  X    X   
Eligibility assessment  X           
Eligibility confirmat ion   X         
Reimbursement  X X X X X X X 
Record/ update AEs      X X X X X 
Schedule next visit  X X X   X  
BEHAVIORAL              
HIV pre - and post - test counseling  X *      
Protocol adherence counseling    X X  X X X 
Medication  use/adherence couns eling    X X    *   
CLINICAL              
Medical  history , review/obtain records   X X X  X X X 
Concomitant medications  X X X  X X X 
Document pre -existing conditions   X X         
Physical examination  X(full) X(full) X (modified)   X(modified)  + (modified ) X (modified)  
Assessment of fetal heart tones  X X X  X   
Provide available test results  X X X  X X X 
Collect Pregnancy Outcomes/MR review       X  
LABORATORY              
 HCV RNA viral load  X X  X  X X X 
HCV Genotype  +       
HCV Resistance testin g   *  * * * 
HBV Testing  X           
CBC  with diff and platelets  X  X (V3, V4)     X 
Creatinine  X   X (V3, V4)      X 
Hepatic Function Panel  X   X (V3, V4)      X 
Lipase  X  X (V3, V4)     X  
Creatinine kinase  X  X (V3, V4)     X 
HIV serology  X       
PT/INR  X  X (V3, V4)     X 
Intensive Plasma PK     X (V3, V5)       
Sparse Plasma PK    X (V4)  X  ^  
DBS for intracellular SOF    X   ^  
PBMC for intracellular SOF    X   ^  
Protein Binding Assay    X (V3, V5)      
STUDY MEDICATION  
            
Provision of Study Medication     X X   *    
Administer Timed dose of study medication    X (V3, V5)      
Review/collect of adherence tools   X X  X   
Collect Remaining Study Medication        X    
*If indicated   
+May be performed or obtained from medical reco rd 
 
 
SOF/VEL in Pregnancy, Version 5.0 60 December 2  , 2020  
 **May be performed during hospital admission for participants who deliver at Magee or applicable procedures 
conducted by phone for participants who deliver at outside locations.  For all participants, a chart review of the 
delivery records will be done as part of the Delivery Visit   
^ If still on study medication at the time of delivery  
 
 
SOF/VEL in Pregnancy, Version 5.0 61 December 2  , 2020  
 APPENDIX II : SCHEDULE OF STUDY VISITS AND EVALUATIONS  (Infant)  
 
 
    Delivery *** iV1 
(Month 1 -3) iV2 
(Month 6)  iV3 
(Month 12)  
ADMINISTRATIVE AND REGULATORY          
Assignment of PTID  X       
Locator information  X X X X 
Demographic information   X     
Reimbursement  X X X X 
Record/ update AEs    X  X X 
Schedule next visit  X X X  
CLINICAL          
Medical history ** X X X X 
Concomitant medications ** X X X X 
Document pre-existing conditions **  X X     
Physical examination ** X X X X 
Collect growth parameters  **  X X X 
Collect Baseline Information ** X    
Provide available test results   X X X 
Developmental Exam /Assessment    X X 
LABORATORY          
 HCV RNA viral l oad X X  X * 
HCV Resistance testing   * * * 
 Sparse PK from cord blood  ^    
 
*If indicate d 
**May be obtained from medical record as applicable  
*** May be performed during hospital admission for infants born at Magee or applicable procedures conducted 
by phone with mother for infants who deliver at outside locations.  For all participants, a chart review of the 
delivery records will be done as part of the Delivery Visit.   
^ If mother on study drug at the time of delivery  and delivers at Magee -Womens Hospi tal 
 
  
 
 
SOF/VEL in Pregnancy, Version 5.0 62 December 2  , 2020  
 Reference List  
 
1. Morse A, Barritt ASt, Jhaveri R. Individual State Hepatitis C Data Supports Expanding 
Screening Beyond Baby Boomers to All Adults. Gastroenterology 2018;154:1850 -1 e2.  
2. Patrick SW, Ba uer AM, Warren MD, Jones TF, Wester C. Hepatitis C Virus Infection Among 
Women Giving Birth - Tennessee and United States, 2009 -2014. MMWR Morb Mortal Wkly Rep 
2017;66:470 -3. 
3. Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection  related to injection 
drug use among persons aged </=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 
2006 -2012. MMWR Morb Mortal Wkly Rep 2015;64:453 -8. 
4. Goldberg D, Ditah IC, Saeian K, et al. Changes in the Prevalence of Hepatitis C Virus 
Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or 
Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology 2017;152:1090 -9 e1.  
5. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C 
Virus in the United States, 2003 -2013. Clin Infect Dis 2016;62:1287 -8. 
6. Benova L, Mohamoud YA, Calvert C, Abu -Raddad LJ. Vertical transmission of hepatitis C 
virus: systematic review and meta -analysis. Clin Infect Dis 2014;59: 765-73. 
7. Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Maternal hepatitis 
B and hepatitis C carrier status and perinatal outcomes. Liver Int 2011;31:1163 -70. 
8. Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pr egnancy 
complications associated with hepatitis C: data from a 2003 -2005 Washington state birth cohort. Am J 
Obstet Gynecol 2008;199:38 e1 -9. 
9. Salemi JL, Whiteman VE, August EM, Chandler K, Mbah AK, Salihu HM. Maternal hepatitis B 
and hepatitis C infecti on and neonatal neurological outcomes. J Viral Hepat 2014;21:e144 -53. 
10. Marcellin P, Boyer N, Gervais A, et al. Long -term histologic improvement and loss of 
detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to 
interferon -alpha therapy. Ann Intern Med 1997;127:875 -81. 
11. Coppola N, De Pascalis S, Pisaturo M, et al. Sustained virological response to antiviral 
treatment in chronic hepatitis C patients may be predictable by HCV -RNA clearance in peripheral 
blood monon uclear cells. J Clin Virol 2013;58:748 -50. 
12. Garcia -Bengoechea M, Basaras M, Barrio J, et al. Late disappearance of hepatitis C virus 
RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained 
response after alpha -interferon therapy. Am J Gastroenterol 1999;94:1902 -5. 
13. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients 
with chronic hepatitis C treated with peginterferon alfa -2a and ribavirin. Gastroenterology 
2010;139:1593 -601. 
14. Manns MP, Pockros PJ, Norkrans G, et al. Long -term clearance of hepatitis C virus following 
interferon alpha -2b or peginterferon alpha -2b, alone or in combination with ribavirin. J Viral Hepat 
2013;20:524 -9. 
15. Poynard T, McHutchison J, Manns M, et a l. Impact of pegylated interferon alfa -2b and 
ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303 -13. 
16. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir -based treatment, with and 
without interfe ron, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol 
Hepatol 2014;12:1349 -59 e13.  
17. Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in 
an extended network of people who inject  drugs in the USA: a modelling study. Lancet Infect Dis 
2018;18:215 -24. 
18. Recommendations for Testing, Managing and Treating Hepatitis C. Infectious Diseases 
Society of America and American Association for the Study of Liver Diseases.  Accessed at: 
http://www.hcvguidelines.org/fullreport  on August 10,2016.  
19. World Health Organization. Global Health Sector Strategies on Viral Hepatitis 2016 -2021. 
Available at: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO -HIV-2016.06 -
eng.pdf;jsessionid=1A0F0BCFBB6FF6F2A34627AAD8C8A6E5?sequence=1 ; Accessed  June 8, 
2019. .  
 
 
SOF/VEL in Pregnancy, Version 5.0 63 December 2  , 2020  
 20. U.S. Department of Health and Human Services. The U.S. National Viral Hepatitis Action 
Plan for 2017 -2020.  Available at: 
https://www.hhs.gov/sites/default/files/National%20Viral%20Hepatitis%20Action%20Plan%202017 -
2020.pdf ; Accessed: June 8, 2019. .  
21. Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and 
management. Am J Obstet Gynecol 2017; 217:B2 -B12. 
22. Clarke JR, Braganza R, Mirza A, et al. Rapid development of genotypic resistance to 
lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999;59:364 -8. 
23. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and 
after pregnancy in low -income, middle -income, and high -income countries: a systematic review and 
meta -analysis. Aids 2012;26:2039 -52. 
24. Krans EE, Zickmund SL, Rustgi VK, Park SY, Dunn SL, Schwarz EB. Screening and 
evaluation of hepatit is C virus infection in pregnant women on opioid maintenance therapy: A 
retrospective cohort study. Subst Abus 2016;37:88 -95. 
25. Laird HJ, Jonassaint NL, Chappell CA, Krans EE. Postpartum Treatment for Chronic 
Hepatitis C Virus Among Women in Medication -Assisted Treatment for Opioid Use Disorder: the 
Potential of an Integrated Medical Home Model. Poster presentation at the IDSOG Annual Meeting, 
August 2019.  
26. Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin 
Perinatol 2015;39:512 -9. 
27. Gilbert EM, Darin KM, Scarsi KK, McLaughlin MM. Antiretroviral Pharmacokinetics in 
Pregnant Women. Pharmacotherapy 2015.  
28. German P, Mo orehead L, Pang P, Vimal M, Mathias A. Lack of a clinically important 
pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives 
norgestimate/ethinyl estradiol in HCV -uninfected female subjects. J Clin Pharmacol 2014;54:1 290-8. 
29. Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C Virus 
Screening Among Children Exposed During Pregnancy. Pediatrics 2018;141.  
30. Chappell CA, Krans EE, Bunge KE, Macio IS, Bogen D, Scarsi KK, Meyn LA, Hillier SL. A 
Phase 1 Study of Ledipasvir/Sofosbuvir in Pregnant Women with Hepatitis C Virus. In: Conferences 
on Retroviruses and Opportunistic Infections; 2010 Mar 4 -7; Seattle, WA; Abstract 87.  
31. Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation -Specific Changes 
in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model 
Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy. Clin Pharmacokinet 
2017;56:1303 -30. 
32. Ward RM, Varner MW. Principles of  Pharmacokinetics in the Pregnant Woman and Fetus. 
Clin Perinatol 2019;46:383 -98. 
33. MacBrayne CE, Kiser JJ. Pharmacologic Considerations in the Treatment of Hepatitis C Virus 
in Persons With HIV. Clin Infect Dis 2016;63 Suppl 1:S12 -23. 
34. Food and Drug Administration. Epclusa Package Insert. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf . Accessed: January 
15, 2019.  
35. Denning J, Corn propst M, Flach SD, Berrey MM, Symonds WT. Pharmacokinetics, safety, 
and tolerability of GS -9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following 
single ascending doses in healthy subjects. Antimicrob Agents Chemother 2013;57:1201 -8. 
36. Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, Pharmacodynamic, and 
Drug -Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin 
Pharmacokinet 2015;54:677 -90. 
37. Feld JJ, Jacobson IM, Hezode C, et al . Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 
5, and 6 Infection. N Engl J Med 2015;373:2599 -607. 
38. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 
3 Infection. N Engl J Med 2015;373:2608 -17. 
 